Dabigatran versus warfarin in patients with atrial fibrillation (scientific article)

cites work (P2860)

Q34135274	'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting
Q48370582	12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke
Q37965481	2011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinician.
Q37989837	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design
Q55263071	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design
Q22306358	2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Q30653045	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures
Q27341873	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society
Q50662583	2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack.
Q34677347	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib
Q57621041	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Q50089557	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.
Q45059153	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Q46658026	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Q38647787	2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
Q64080237	2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension
Q58550785	2018 Korean Guideline of Atrial Fibrillation Management
Q38845403	80-year-old man with massive leg swelling
Q38685671	A 'reluctant' critical review: 'Manual for evidence-based clinical practice (2015)'.
Q38561041	A 35-year journey to evidence-based medicine: a personal story
Q38939246	A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation
Q90586842	A Case of Rapid Malignant Brain Swelling Subacutely After Reperfusion Therapy for Internal Carotid Artery Occlusion
Q40952220	A Comparison of Dabigatran With Warfarin for Stroke Prevention in Atrial Fibrillation in an Asian Population
Q40315181	A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin
Q40771901	A Decision Analysis of Percutaneous Left Atrial Appendage Occlusion Relative to Novel and Traditional Oral Anticoagulation for Stroke Prevention in Patients with New-Onset Atrial Fibrillation
Q40973888	A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark
Q41538362	A Multilevel Analysis of Real-World Variations in Oral Anticoagulation Initiation for Atrial Fibrillation in Valencia, a European Region
Q38691618	A New Generation of Antiplatelet, and Anticoagulant Medication and the Implications for the Dental Surgeon
Q50034024	A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents.
Q45022458	A Prospective Cohort Study of Idarucizumab for Reversal of Dabigatran-Associated Hemorrhage
Q47094449	A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry.
Q37444709	A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran
Q59792032	A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation
Q37114593	A Review Of Clinical Trials On LARIAT Device
Q38199371	A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience
Q50531960	A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism.
Q38854836	A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation.
Q36085531	A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Q91601311	A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin
Q37876398	A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.
Q50082606	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
Q35849625	A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy
Q42264521	A case of a slightly symptomatic exfoliative oesophagitis
Q35986742	A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits
Q36203602	A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation
Q34109813	A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?
Q36952091	A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation
Q44979778	A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation
Q37150670	A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation
Q34146593	A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice
Q43436739	A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke
Q93031573	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa
Q50485303	A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.
Q41872517	A left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban.
Q40964074	A long and narrow pulmonary vein thrombus attached to the wall of a pulmonary vein
Q30248612	A meta-analysis for efficacy and safety evaluation of transcatheter left atrial appendage occlusion in patients with nonvalvular atrial fibrillation
Q37983093	A meta-analysis to determine the effect of anticoagulation on mortality in patients with blunt head trauma
Q39372785	A mouse bleeding model to study oral anticoagulants.
Q37562899	A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
Q40964586	A network of pulmonary vein thrombi is a risk factor for ischemic stroke, especially after cardiac surgery: A case report and mini review
Q37970791	A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk.
Q51091008	A new class of powerful and informative simultaneous confidence intervals.
Q38087192	A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice
Q37312021	A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin
Q58756591	A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants
Q38155157	A new paradigm shift in antithrombotic therapy
Q34200483	A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
Q35568298	A novel association of adenosine deaminase with paroxysmal atrial fibrillation: a propensity score analysis from a case-control study
Q38988119	A pharmacotherapy review of the novel, oral antithrombotics
Q36164759	A pilot randomized controlled trial of a decision support tool to improve the quality of communication and decision-making in individuals with atrial fibrillation
Q36618123	A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.
Q35139947	A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).
Q33161569	A primer on arrhythmias in patients with hypertrophic cardiomyopathy
Q34571082	A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time
Q61446878	A prospective multicenter observational study evaluating the risk of periendoscopic events in patients using anticoagulants: the Osaka GIANT Study
Q90242051	A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
Q50501003	A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.
Q51618025	A rapid pro-hemostatic approach to overcome direct oral anticoagulants.
Q35991733	A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation
Q37942759	A regulator's view of comparative effectiveness research
Q38132927	A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Q38074330	A review of oral anticoagulants in patients with atrial fibrillation
Q26781162	A review of the LARIAT device: insights from the cumulative clinical experience
Q28087744	A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
Q36627535	A review of the role of anticoagulation in the treatment of peripheral arterial disease
Q33949244	A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks
Q53972012	A score for paroxysmal atrial fibrillation in acute ischemic stroke.
Q36988011	A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin.
Q46612551	A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation
Q46303154	A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma
Q84198989	A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits
Q51255753	A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability.
Q88691821	A surgeon's guide to anticoagulant and antiplatelet medications part one: warfarin and new direct oral anticoagulant medications
Q64888900	A survey of opinion: When to start oral anticoagulants in patients with acute ischaemic stroke and atrial fibrillation?
Q48506800	A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: the SELECT study
Q64091902	AF in Cancer Patients: A Different Need for Anticoagulation?
Q57170002	AMPK: Potential Therapeutic Target for Ischemic Stroke
Q38650658	ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives.
Q41118456	ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention
Q95479053	ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients
Q92186598	Ablation Versus Medical Therapy for Atrial Fibrillation in the Elderly: A Propensity Score-Matched Comparison
Q36522665	Ablation for atrial fibrillation in combination with left atrial appendage closure: first results of a feasibility study
Q28068321	Ablation of Atrial Fibrillation in Combination with Left Atrial Appendage Occlusion in A Single Procedure. Rationale and Technique
Q38906252	Ablation protocols and ancillary procedures in tumor ablation therapy: consensus from Japanese experts
Q50660842	Accelerating the pulse of cardiovascular R&D.
Q92971778	Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154 000 Individuals
Q33687894	Acquired hemophilia with inhibitors presenting as an emergency: misinterpretation of clotting results during direct oral anticoagulation
Q43508776	Activity recommendations for anticoagulated patients may differ, but should be based on accurate data interpretation.
Q64101061	Acute Lower Gastrointestinal Bleeding in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice: Characteristics and Clinical Outcome
Q48100999	Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature
Q34738347	Acute airway obstruction due to spontaneous intrathyroid hemorrhage precipitated by anticoagulation therapy
Q27026743	Acute cardioembolic cerebral infarction: answers to clinical questions
Q37857867	Acute cardioembolic stroke: an update.
Q38086096	Acute coronary syndromes: advances in antithrombotics
Q54561846	Acute ischemic stroke following cardioversion in a patient receiving dabigatran.
Q38065699	Acute management of bleeding in patients on novel oral anticoagulants.
Q35211215	Acute myocardial infarction after switching from warfarin to dabigatran
Q53113310	Acute pulmonary emboli in a patient on long-term dabigatran therapy.
Q38228428	Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?
Q38005465	Acute stroke management in patients taking dabigatran.
Q52343211	Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation.
Q34725585	Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012
Q41503389	Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation
Q37253651	Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants
Q53100422	Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice.
Q44674554	Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care
Q41594904	Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration
Q90639018	Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study
Q37738786	Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration
Q38017567	Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents
Q38833151	Adherence to long-term anticoagulation treatment, what is known and what the future might hold
Q36332351	Adherence to oral anticoagulant therapy in secondary stroke prevention - impact of the novel oral anticoagulants
Q36179688	Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol.
Q87478060	Adherence to warfarin treatment among patients with atrial fibrillation
Q38655951	Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study
Q40351360	Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists
Q39867468	Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation
Q38127644	Advances and challenges in treatment and prevention of ischemic stroke
Q38790302	Advances in Left Atrial Appendage Occlusion Strategies
Q38967468	Advances in Oral Coagulants
Q37242531	Advances in genetics 2010.
Q42723607	Advances in oral anticoagulants: focus on dabigatran etexilate
Q42750499	Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
Q38380852	Advances in stroke prevention
Q38097388	Advances in stroke prevention in atrial fibrillation: enhanced risk stratification combined with the newer oral anticoagulants.
Q42777572	Advances in the Pharmacologic Management of Atrial Fibrillation
Q38076142	Advances in the management of atrial fibrillation.
Q39453949	Advances in transfusion medicine: gastrointestinal bleeding
Q35750181	Advancing cardiovascular research.
Q38151264	Advantages and limitations of the new anticoagulants
Q37495633	Adverse Outcomes from Atrial Fibrillation;Mechanisms, Risks, and Insights Learned from Therapeutic Options
Q38085222	Adverse drug events as a cause of hospitalization in older adults
Q92102797	Adverse events associated with nonsteroidal anti-inflammatory drug use among patients taking oral anticoagulants
Q42681549	Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic
Q51132669	Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study.
Q90532716	Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) databa
Q37495783	Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants
Q47305494	Age- and weight-adjusted warfarin initiation nomogram for ischaemic stroke patients
Q45757467	Alcohol intake and prognosis of atrial fibrillation
Q35772034	Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting
Q38631109	All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
Q49829711	All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants.
Q37066818	Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology
Q38125860	Almanac 2013: cardiac arrhythmias and pacing
Q37480667	Alternative to oral dicoumarin anticoagulants: Considerations in dental care
Q38118483	Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Q37772227	Alternatives to warfarin--the next generation of anticoagulants.
Q30425918	American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association
Q36198941	Amplatzer Cardiac Plug for Stroke Prevention in Patients with Atrial Fibrillation and Bigger Left Atrial Appendix Size
Q58804555	An Earnest Search for Atrial Fibrillation Patients Without Thromboembolic Risk
Q97517227	An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease
Q36108384	An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation
Q27027953	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
Q38167048	An explanation of recommendation differences: illustrations from recent atrial fibrillation guidelines
Q44565267	An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran
Q38366102	An overview of left atrial appendage occlusion devices
Q38842430	An update on laboratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma
Q37328680	An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes
Q40959484	Analysis of anticoagulant prescribing in non-valvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection
Q38032226	Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital
Q38773669	Analytical Management of Patients Undergoing Oral Anticoagulant Therapy Could Have a Strong Impact on Clinical Outcomes: A Follow-up Study.
Q42646075	Anaphylaxis after Idarucizumab Infusion
Q38747585	Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
Q36050347	Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease
Q39390613	Anesthetic Management of Patients Undergoing Percutaneous Endocardial and Epicardial Left Atrial Appendage Occlusion
Q38813195	Animal models of spontaneous intracerebral hemorrhage
Q90663188	Antagonists of Vitamin K-Popular Coumarin Drugs and New Synthetic and Natural Coumarin Derivatives
Q38791637	Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection
Q47863451	Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Q38747406	Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation
Q50075292	Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views.
Q37935785	Anti-thrombotic therapy in infective endocarditis.
Q38236837	Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage
Q92098126	Anticoagulant Utilization and Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular Atrial Fibrillation
Q38009321	Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease
Q37914925	Anticoagulant management in the cardiovascular setting
Q38008152	Anticoagulant therapy for patients with ischaemic stroke
Q38079779	Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment
Q36176578	Anticoagulants for stroke prevention in nonvalvular atrial fibrillation: new agents and an updated understanding
Q38028855	Anticoagulants in atrial fibrillation patients with chronic kidney disease
Q38074333	Anticoagulants in patients with atrial fibrillation and end-stage renal disease
Q90167323	Anticoagulants' Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study
Q38107945	Anticoagulants: A Review of the Pharmacology, Dosing, and Complications
Q47124161	Anticoagulating atrial fibrillation patients: is there a kidney-friendly choice?
Q37919151	Anticoagulating obese patients in the modern era.
Q38802398	Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit
Q47713063	Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials
Q52325500	Anticoagulation Management After Transcatheter and Surgical Valve Replacement.
Q37336382	Anticoagulation Quality and Complications of using Vitamin K Antagonists in the Cardiac Surgery Outpatient Clinic
Q37578264	Anticoagulation Stability Depends on CHADS2 Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation
Q37218884	Anticoagulation Therapy Considerations in Factor VII Deficiency
Q39148821	Anticoagulation Therapy and NOACs in Heart Failure
Q96137475	Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry
Q99237562	Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review
Q47984703	Anticoagulation after coronary stenting: a systemic review
Q37496051	Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry
Q36900966	Anticoagulation and population risk of stroke and death in incident atrial fibrillation: a population-based cohort study.
Q34187660	Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
Q27021871	Anticoagulation drug therapy: a review
Q30975560	Anticoagulation for Atrial Fibrillation in Patients with Cerebral Microbleeds
Q57721119	Anticoagulation for Atrial Fibrillation: Is This the End of Warfarin? Not Just Yet
Q46725196	Anticoagulation for atrial fibrillation : the future has begun
Q27010464	Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?
Q37738233	Anticoagulation for mechanical heart valves in patients with and without atrial fibrillation
Q47448340	Anticoagulation for noncardiac indications in neurologic patients: comparative use of non-vitamin k oral anticoagulants, low-molecular-weight heparins, and warfarin
Q27025111	Anticoagulation for prosthetic valves
Q37047213	Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement
Q36458782	Anticoagulation in Atrial Fibrillation
Q36458853	Anticoagulation in Atrial Fibrillation - Current Concepts
Q49963915	Anticoagulation in Glaucoma Surgery.
Q28087068	Anticoagulation in Heart Failure: a Review
Q36381170	Anticoagulation in Heart Failure: a Review.
Q33936087	Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants
Q61454254	Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study
Q36287614	Anticoagulation in acute ischemic stroke: A systematic search
Q28315636	Anticoagulation in atrial fibrillation
Q47581328	Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations
Q38055261	Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.
Q52641165	Anticoagulation in atrial fibrillation with heart failure.
Q37082589	Anticoagulation in atrial fibrillation: the present and the future
Q87958735	Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice
Q38044305	Anticoagulation in heart failure: current status and future direction
Q57147264	Anticoagulation in patients with dilated cardiomyopathy, low ejection fraction, and sinus rhythm: back to the drawing board
Q55506528	Anticoagulation in the Elderly.
Q42922806	Anticoagulation in the elderly
Q43622937	Anticoagulation in the setting of intracerebral hemorrhage: controversies in resuming therapy
Q34642367	Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan
Q37961823	Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption.
Q48157907	Anticoagulation prescribing patterns in patients with cancer
Q34469002	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Q49502957	Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
Q37992920	Anticoagulation therapy. Dabigatran and risk of myocardial infarction
Q38124868	Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease
Q34017336	Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage
Q38013666	Anticoagulation-related intracranial hemorrhages
Q38670098	Anticoagulation-related nephropathy
Q56627180	Antikoagulation
Q90312460	Antiphospholipid Syndrome and Kidney Involvement: New Insights
Q55891386	Antiphospholipid syndrome
Q38535999	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation
Q93379484	Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare
Q38909618	Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke
Q38075455	Antiplatelet medications and evolving antithrombotic medication
Q90170007	Antiplatelet, anticoagulant or both? A tool for pharmacists
Q42966185	Antiplatelets and anticoagulants
Q64992024	Antithrombotic Dilemmas after Left Atrial Appendage Occlusion Watchman Device Placement.
Q34670524	Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke
Q57764364	Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums
Q98613603	Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
Q37167694	Antithrombotic Usage Patterns in the Era of New Oral Anticoagulant Options for Atrial Fibrillation
Q37449732	Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
Q42772493	Antithrombotic and anticoagulation therapy after stroke and transient ischemic attacks
Q37695400	Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events
Q26827113	Antithrombotic management of atrial fibrillation in the elderly
Q98383430	Antithrombotic management of patients with atrial fibrillation-Dutch anticoagulant initiatives anno 2020
Q35142419	Antithrombotic medication for cardioembolic stroke prevention
Q39295736	Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention
Q38272769	Antithrombotic therapy after left atrial appendage closure
Q35752573	Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Q38407316	Antithrombotic therapy for left ventricular assist devices in adults: a systematic review.
Q38108234	Antithrombotic therapy for patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention: a review
Q37990454	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves
Q38059909	Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation
Q47978618	Antithrombotic therapy for stroke prevention in patients with heart failure
Q36876659	Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice.
Q34362901	Antithrombotic therapy in cardiac embolism
Q38851232	Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges.
Q89641591	Antithrombotic therapy in patients with non-traumatic intracerebral haemorrhage and atrial fibrillation: A retrospective study
Q37222361	Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I c
Q38390896	Antithrombotic treatment at onset of stroke with atrial fibrillation, functional outcome, and fatality: a systematic review and meta-analysis.
Q37721619	Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
Q53093982	Antithrombotic treatment for stroke associated with antiphospholipid antibodies.
Q33427274	Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach
Q64228894	Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study
Q38081257	Antithrombotics for stroke prevention in non-valvular atrial fibrillation: an update
Q38232135	Antithrombotics in atrial fibrillation and coronary disease
Q38164671	Antithrombotics in heart failure with reduced ejection fraction and normal sinus rhythm: an evidence appraisal
Q48158928	Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach
Q87439250	Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials
Q43415636	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial
Q36027550	Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients
Q37953152	Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence
Q92279167	Apixaban in Comparison to Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
Q90410581	Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation
Q37765608	Apixaban in acute coronary syndromes
Q37495983	Apixaban in patients with Atrial Fibrillation: A Systematic Review
Q38876376	Apixaban to prevent stroke in patients with atrial fibrillation: a review
Q36030528	Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial
Q38566808	Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation
Q40435479	Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation
Q33727817	Apixaban, concomitant medicines and spontaneous reports of haemorrhagic events
Q48149969	Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Q89539076	Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation
Q38020739	Apixaban: a novel oral inhibitor of factor Xa.
Q38107180	Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Q34497581	Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Q34666269	Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions
Q55229155	Approaches to Left Atrial Appendage Closure: Device Design, Performance, and Limitations.
Q39456319	Approaches to prevent bleeding associated with anticoagulants: current status and recent developments
Q94355271	Approche à l’égard des nouveaux anticoagulants oraux en pratique familiale: 1 partie : Comparer les options
Q94355279	Approche à l’égard des nouveaux anticoagulants oraux en pratique familiale: 2 partie : Répondre aux questions souvent posées
Q99711253	Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration
Q37047110	Appropriateness of Dabigatran and Rivaroxaban Prescribing for Hospital Inpatients.
Q47864472	Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience
Q64912480	Appropriateness of dabigatran dosing in patients with nonvalvular atrial fibrillation (NVAF): A retrospective study conducted in a tertiary care university hospital in the eastern province of Saudi Arabia.
Q38826010	Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation
Q33806117	Are the Results of the RE-LY Trial Reliable?
Q35062047	Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?
Q26750467	Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants
Q28072723	Asian strategy for stroke prevention in atrial fibrillation
Q37998110	Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants
Q92500105	Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
Q64104355	Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
Q24619070	Assessing bleeding risk in patients taking anticoagulants
Q38821933	Assessment of Direct Oral Anticoagulant Prescribing and Monitoring Pre- and Post-Implementation of a Pharmacy Protocol at a Community Teaching Hospital
Q39321699	Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
Q92727485	Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation
Q51543782	Assessment of left and right atrial 3D hemodynamics in patients with atrial fibrillation: a 4D flow MRI study.
Q38754719	Assessment of novel oral anticoagulant use within a community teaching hospital
Q37902507	Assessment of oral antithrombotic therapy by platelet function testing
Q40135115	Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina
Q47874270	Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
Q91577650	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
Q58094925	Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran
Q30909780	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Q37578065	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation
Q47838584	Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality
Q96029587	Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage
Q49833980	Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding.
Q90667785	Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation
Q90242435	Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding
Q93205767	Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function
Q39378104	Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding
Q93365406	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II
Q39240697	Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis
Q35608507	Association of cyclooxygenase-2 genetic variant with cardiovascular disease
Q35335927	Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA.
Q92984217	Association of stroke and bleed events in non-valvular atrial fibrillation patients with direct oral anticoagulant prescriptions in NHS England between 2013 and 2016
Q43237598	At last, a RE-LYable alternative to warfarin for atrial fibrillation
Q38065252	Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease.
Q50077941	Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.
Q57813067	Atrial Fibrillation
Q37496293	Atrial Fibrillation - A Common Ground for Neurology and Cardiology
Q48525838	Atrial Fibrillation Ablation and its Impact on Stroke
Q37495856	Atrial Fibrillation Associated with Heart Failure, Stroke and Mortality.
Q37496257	Atrial Fibrillation Complicating Acute Coronary Syndromes
Q37469064	Atrial Fibrillation In Heart Failure: New Directions In Diagnosis, Risk Assessment And Risk Reduction
Q42374370	Atrial Fibrillation Screening in Nonmetropolitan Areas Using a Telehealth Surveillance System With an Embedded Cloud-Computing Algorithm: Prospective Pilot Study
Q40072744	Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy
Q28067128	Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels
Q36956791	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms
Q37496206	Atrial Fibrillation and Oral Anticoagulation in Chronic Kidney Disease
Q37274009	Atrial Fibrillation and Race - A Contemporary Review
Q90229012	Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
Q49428555	Atrial Fibrillation for the Neurologist: Preventing both Ischemic and Hemorrhagic Strokes.
Q92802219	Atrial Fibrillation in Older People: Concepts and Controversies
Q35438395	Atrial Fibrillation in the Young: A Neurologist's Nightmare
Q53927463	Atrial Fibrillation: State of the Art in 2017 - Shifting Paradigms in Pathogenesis, Diagnosis, Treatment and Prevention.
Q56607936	Atrial fibrillation
Q82941599	Atrial fibrillation
Q94031094	Atrial fibrillation
Q91797486	Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk
Q41341319	Atrial fibrillation and chronic kidney disease: focus on rivaroxaban
Q39635843	Atrial fibrillation and diabetes mellitus. Correlation, co-existence, and coagulation therapy
Q37952604	Atrial fibrillation and heart failure in the elderly
Q38224401	Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation.
Q36836836	Atrial fibrillation and stroke: the evolving role of rhythm control
Q36551541	Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence
Q37975985	Atrial fibrillation and vascular disease--a bad combination
Q37635243	Atrial fibrillation anticoagulation care in a large urban family medicine practice
Q26799571	Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options
Q38032181	Atrial fibrillation in heart failure
Q37043226	Atrial fibrillation in heart failure: The sword of Damocles revisited.
Q27010588	Atrial fibrillation in heart failure: an innocent bystander?
Q38180390	Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation
Q26784426	Atrial fibrillation in heart failure: what should we do?
Q54720771	Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?
Q26778659	Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives
Q37882717	Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly
Q86856130	Atrial fibrillation in the elderly
Q64251820	Atrial fibrillation in the elderly
Q51026059	Atrial fibrillation in the elderly: a review.
Q30241862	Atrial fibrillation in women: treatment
Q28076170	Atrial fibrillation management in older heart failure patients: a complex clinical problem
Q88478475	Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis
Q39046134	Atrial fibrillation with high ventricular rate in emergency room: What's the best strategy for treatment?
Q45839045	Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection.
Q38006746	Atrial fibrillation, stroke, and quality of life
Q43216536	Atrial fibrillation: A promising new anticoagulant for stroke prevention
Q26851235	Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute
Q37923979	Atrial fibrillation: an epidemic in the elderly
Q37848443	Atrial fibrillation: pathophysiology and current therapy
Q38168183	Atrial fibrillation: relieving symptoms and managing risk.
Q33359459	Atrial fibrillation: state of the art.
Q33589724	Atrial high-rate episodes and stroke prevention
Q55192415	A practical guide on how to handle patients with bleeding events while on oral antithrombotic treatment.
Q33936118	Balancing antiplatelet and anticoagulant therapies in patients with cardiovascular disease
Q37561924	Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution?
Q38161519	Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
Q36173753	Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants
Q38264835	Balancing ischaemia and bleeding risks with novel oral anticoagulants
Q51244065	Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study.
Q43811395	Barriers to warfarin use for stroke prevention in patients with atrial fibrillation in Hong Kong
Q90193716	Baseline D-Dimer Levels as a Risk Assessment Biomarker for Recurrent Stroke in Patients with Combined Atrial Fibrillation and Atherosclerosis
Q38598620	Baseline characteristics and event rates among anticoagulated patients with atrial fibrillation in practice and pivotal NOAC trials
Q35673546	Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice
Q35181596	Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
Q34437785	Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis
Q43762811	Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.
Q38200587	Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation
Q33646770	Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Q38799138	Betrixaban - the next direct factor Xa inhibitor?
Q36860112	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa).
Q48168933	Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation
Q38692411	Beyond warfarin: The advent of new oral anticoagulants
Q88785493	Beyond warfarin: The advent of new oral anticoagulants
Q35885429	Bilateral Spontaneous Hyphema, Vitreous Hemorrhage, and Choroidal Detachment With Concurrent Dabigatran Etexilate Therapy
Q35939026	Biochemistry and biology of mammalian DNA methyltransferases
Q64238872	Biomarker for Ischemic Stroke Using Metabolome: A Clinician Perspective
Q53235988	Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation.
Q33392973	Bivalirudin: a review of the pharmacology and clinical application
Q38117731	Bleeders, bleeding rates, and bleeding score
Q60313497	Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database
Q38458642	Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).
Q35335836	Bleeding and clotting in hereditary hemorrhagic telangiectasia
Q57173742	Bleeding by the numbers: The utility and the limitations of bleeding scores, bleeding prediction tools, and bleeding case definitions
Q36785642	Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments
Q33841770	Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study
Q38163400	Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital
Q53099910	Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia.
Q88599305	Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation
Q57064376	Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Q45328731	Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran
Q37897674	Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
Q37868373	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis
Q38087193	Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants
Q38600440	Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data
Q38165077	Bleeding risk prediction models in atrial fibrillation.
Q47097414	Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
Q47803747	Bleeding with oral anticoagulant dabigatran is highly associated with occult cancers in atrial fibrillation patients
Q53140080	Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.
Q36836404	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Q37930460	Blood coagulation factor XII--a neglected player in stroke pathophysiology
Q37999723	Blood component support in acquired coagulopathic conditions: is there a method to the madness?
Q45924284	Body piercing and psychopathology: a review of the literature.
Q38148437	Brain regulation of thrombosis and hemostasis: from theory to practice
Q38921966	Burden of atrial fibrillation: a retrospective review of patients presenting to acute medical services.
Q37158307	Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention
Q37495770	CHADS2 and CHA2DS2Vasc-Score in Peripheral Systemic Embolism
Q93092195	Calibrated Automated Thrombinography (CAT), a Tool to Identify Patients at Risk of Bleeding during Anticoagulant Therapy: A Systematic Review
Q39419954	Can dabigatran improve blood pressure control?
Q33516708	Can we improve outcomes in AF patients by early therapy?
Q37975988	Can we predict the occurrence of atrial fibrillation?
Q64239359	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial
Q85076497	Cardiac amyloidosis: evolving approach to diagnosis and management
Q37701918	Cardiac drug therapy-considerations in the elderly
Q42363989	Cardiac tachyarrhythmias and anaesthesia: General principles and focus on atrial fibrillation
Q30238631	Cardioembolic Stroke
Q42173112	Cardioembolic sources in stroke patients in South of Brazil
Q38176144	Cardioembolic stroke: practical considerations for patient risk management and secondary prevention
Q37777342	Cardiological evaluation after cerebral ischaemia : Consensus statement of the Working Group Heart and Brain of the German Cardiac Society-Cardiovascular Research (DGK) and the German Stroke Society (DSG).
Q51601886	Cardiorenal medicine in the changing health system.
Q92218889	Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?
Q38614547	Cardiovascular causes of emergency neurology presenting to an ICU.
Q47374630	Cardiovascular complications of multiple myeloma in the elderly.
Q53150011	Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).
Q39068770	Cardiovascular diseases in China: Current status and future perspectives
Q37803337	Cardiovascular drug therapy in the elderly: benefits and challenges
Q93164270	Cardiovascular effects and safety of (non-aspirin) NSAIDs
Q51795314	Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin.
Q88550930	Cardiovascular outcome in type 2 diabetes and atrial fibrillation
Q30680968	Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment
Q31138544	Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey
Q37114570	Cardioversion Of Atrial Fibrillation And Oral Anticoagulation
Q28078509	Cardioversion in Non-Valvular Atrial Fibrillation
Q48739342	Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin.
Q27025527	Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety
Q37724306	Carotid thromboembolism associated with nephrotic syndrome treated with dabigatran
Q37340101	Case report: dabigatran-associated gynecologic bleeding
Q39036323	Catheter Ablation for Atrial Fibrillation in Patients With Watchman Left Atrial Appendage Occlusion Device: Results from a Multicenter Registry
Q31054764	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
Q35860841	Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation
Q31108748	Cerebral Microhemorrhages: Significance, Associations, Diagnosis, and Treatment
Q37662448	Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies?
Q30570918	Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk
Q37082606	Cerebral microbleeds: a new dilemma in stroke medicine
Q37435248	Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations
Q64054095	Cerebrovascular events, bleeding complications and device related thrombi in atrial fibrillation patients with chronic kidney disease and left atrial appendage closure with the WATCHMAN™ device
Q26765949	Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review
Q37978627	Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage
Q37373007	Challenges from Variation across Regions in Cost Effectiveness Analysis in Multi-Regional Clinical Trials
Q47776628	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention
Q41843287	Challenging pulmonary embolism - A new generation of oral anticoagulants
Q49022603	Changes in Warfarin Sensitivity During Decompensated Heart Failure and Chronic Obstructive Pulmonary Disease.
Q40280190	Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
Q64078080	Changes in renal function and occurrence of contrast-induced nephropathy after percutaneous coronary interventions in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants or warfarin
Q35850235	Changes in stroke epidemiology, prevention, and treatment
Q37831318	Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
Q33957383	Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis
Q96958962	Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF
Q89513783	Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
Q35690525	Characteristics of Symptomatic Intracranial Hemorrhage in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulant Therapy
Q91834745	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
Q45008140	Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.
Q39065102	Chemical transmitter systems in the brain
Q41527939	Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study
Q48554320	Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
Q28074445	Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know
Q38723866	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
Q38723869	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
Q38372780	Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation
Q50002162	Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
Q57750151	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Q57807713	Claims data studies of direct oral anticoagulants can achieve balance in important clinical parameters only observable in electronic health records
Q35638248	Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation
Q38716973	Clinical Perspectives on Targeting Therapies for Personalized Medicine
Q88866804	Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease
Q91120837	Clinical analysis of antithrombotic treatment and occurrence of stroke in elderly patients with nonvalvular persistent atrial fibrillation
Q28077788	Clinical and Economic Implications of AF Related Stroke
Q33389619	Clinical and management challenges in preventing venous thromboembolism in health systems: a case-based panel discussion
Q38069956	Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation
Q53668632	Clinical and radiological course of intracerebral haemorrhage associated with the new non-vitamin K anticoagulants.
Q91653401	Clinical characteristics and antithrombotic prescription in elderly hospitalized atrial fibrillation patients: A cross-sectional analysis of a Swedish single-center clinical cohort
Q34694778	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
Q36137613	Clinical considerations of anticoagulation therapy for patients with atrial fibrillation
Q30743371	Clinical course of cerebral sinus venous thrombosis. Data from a monocentric cohort study over 15 years
Q33754903	Clinical experience of life-threatening dabigatran-related bleeding at a large, tertiary care, academic medical center: a case series
Q44522283	Clinical experience with oral versus intravenous vitamin K for warfarin reversal
Q102210978	Clinical factors associated with safety and efficacy in patients receiving direct oral anticoagulants for non-valvular atrial fibrillation
Q34621707	Clinical implications of recent trials on anticoagulation in patients with atrial fibrillation
Q38757405	Clinical implications of reversal agents for direct oral anticoagulants
Q39456624	Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants
Q47211981	Clinical manifestations and outcomes of severe warfarin overanticoagulation: from the EWA study
Q38419246	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
Q41359271	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial
Q39702253	Clinical pre-test of a computerised antithrombotic risk assessment tool for stroke prevention in atrial fibrillation patients: giving consideration to NOACs
Q64104985	Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review
Q37507967	Clinical problems with antithrombotic therapy for endoscopic submucosal dissection for gastric neoplasms
Q39000594	Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure
Q33750028	Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management
Q37609046	Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation.
Q44825076	Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT.
Q43238410	Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT.
Q39703408	Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?
Q38095871	Clinical update on the management of atrial fibrillation.
Q38128366	Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban
Q36356624	Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study.
Q27011524	Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation
Q35070830	Clinician's guide to the updated ABCs of cardiovascular disease prevention
Q37887815	Clopidogrel hydrogen sulphate for atrial fibrillation
Q38247224	Clostridium colitis: challenges in diagnosis and treatment
Q51183134	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices.
Q34571099	Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran
Q36968781	Coagulation assessment with the new generation of oral anticoagulants
Q26799394	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?
Q57060141	Cognitive dysfunction in atrial fibrillation
Q45861558	Combined oral anticoagulant and antiplatelet treatment: need for an evidence-based approach
Q37690631	Combined oral anticoagulants and antiplatelets: benefits and risks
Q53655058	Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome.
Q87871432	Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection
Q48103834	Combining value of information analysis and ethical argumentation in decisions on participation of vulnerable patients in clinical research.
Q38666884	Comorbidity of atrial fibrillation and heart failure
Q40229719	Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
Q42746443	Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis.
Q42689291	Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation
Q92692177	Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population
Q42651838	Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison
Q27010166	Comparative effectiveness and implementation research: directions for neurology
Q37012525	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Q37527133	Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol
Q39151928	Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation.
Q37307689	Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Q87636202	Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation
Q36896927	Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses
Q49189865	Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.
Q39453858	Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation
Q40057144	Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Q92867382	Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
Q36317589	Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation
Q92782907	Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis
Q27330363	Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model
Q26746233	Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism
Q35550883	Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
Q38907884	Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study
Q56964574	Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation
Q90003034	Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system
Q61443927	Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
Q42697506	Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study
Q38790430	Comparing Antiarrhythmic Drugs and Catheter Ablation for Treatment of Atrial Fibrillation
Q31131255	Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data
Q38061872	Comparing clinicians' use of an anticoagulation management service and usual care in ambulatory oncology.
Q43978668	Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials
Q37608355	Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation: A systematic review and meta-analysis of observational
Q36153857	Comparison of Approaches for Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation: Network Meta-Analyses of Randomized Controlled Trials
Q36587229	Comparison of Atrial Fibrillation in the Young versus That in the Elderly: A Review
Q37528205	Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients
Q47658902	Comparison of Changes in Anxiety and Depression Level Between Dabigatran and Warfarin Use in Patients With Atrial Fibrillation
Q60925946	Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States
Q90140650	Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting
Q89604773	Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists
Q47803775	Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases
Q39965332	Comparison of aspirin and Naoxintong Capsule () with adjusted-dose warfarin in elderly patients with high-risk of non-valvular atrial fibrillation and genetic variants of vitamin K epoxide reductase
Q47769200	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial
Q90448568	Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database
Q49189568	Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy.
Q86712036	Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
Q35232308	Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States
Q92674695	Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
Q64917816	Comparison of direct oral anticoagulants and warfarin regarding midterm adverse events in patients with atrial fibrillation undergoing catheter ablation.
Q50191220	Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Q48285817	Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register
Q40693950	Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin
Q41464704	Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
Q49499951	Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.
Q40932896	Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction
Q33995194	Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic
Q96136936	Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States
Q40100257	Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease study and the Cockcroft-Gault equation in patients with heart failure.
Q49614502	Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations.
Q45139213	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Q38185977	Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Q36947797	Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort stu
Q39637963	Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials
Q40267269	Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation
Q41195252	Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial
Q35079761	Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.
Q55528580	Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation.
Q53778407	Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers.
Q38592125	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
Q35609742	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
Q44742435	Concerns about storage and application of dabigatran and rivaroxaban
Q82716944	Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation
Q38156338	Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation
Q37148702	Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation
Q49936547	Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?
Q39409421	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus
Q30251866	Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs
Q35118898	Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation
Q38060566	Contemporary Anticoagulation Reversal Focus on Direct Thrombin Inhibitors and Factor Xa Inhibitors
Q35026442	Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches?
Q37833073	Contemporary management of transient ischemic attack: role of the pharmacist
Q38648529	Contemporary measures to reduce the risk of embolic events in patients with atrial fibrillation.
Q47547612	Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting
Q28541487	Continuation of dabigatran therapy in "real-world" practice in Hong Kong
Q40400905	Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis
Q34691799	Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter
Q35836747	Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation
Q92188853	Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches
Q35570827	Controversies in cardioembolic stroke
Q46663237	Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation
Q42112056	Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice?
Q36553553	Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism
Q36370296	Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials
Q39443618	Cost Effectiveness of Implantable Cardiac Monitor-Guided Intermittent Anticoagulation for Atrial Fibrillation: An Analysis of the REACT.COM Pilot Study.
Q35832134	Cost considerations in the management of atrial fibrillation - impact of dronedarone
Q34604533	Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings
Q86299920	Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control
Q38148500	Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants
Q36382393	Cost of atrial fibrillation: invasive vs non-invasive management in 2012
Q42671198	Cost of dabigatran for atrial fibrillation
Q37495861	Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation
Q39091796	Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
Q92423311	Cost-Effectiveness Analysis of Oral Anticoagulants in Stroke Prevention among Patients with Atrial Fibrillation in Taiwan
Q88482368	Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives
Q36657598	Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial Fibrillation
Q88385902	Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective
Q55312336	Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
Q92965803	Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data
Q38529659	Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation
Q37015495	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL.
Q62831292	Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
Q35717518	Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist
Q38598138	Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries
Q36119172	Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation
Q37303759	Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemia
Q35234175	Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany
Q37184310	Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
Q90135462	Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
Q44769550	Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
Q92415495	Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
Q36475213	Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
Q40523358	Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting
Q30598904	Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital
Q35841464	Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
Q34321590	Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation
Q38713953	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review
Q44784933	Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
Q38042441	Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
Q46008192	Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Q37299398	Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting
Q38020935	Cost-effectiveness of stroke treatments and secondary preventions
Q35885128	Costs and clinical consequences of suboptimal atrial fibrillation management
Q86056966	Cranial and non-cranial embolism: incidence in hospitalised patients in Germany
Q28543133	Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design
Q26799691	Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism
Q38703260	Cross-cultural adaptation and content validation of START.
Q93046538	Current Anticoagulant Usage Patterns and Determinants in Korean Patients with Nonvalvular Atrial Fibrillation
Q61804277	Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants
Q88432020	Current State of Left Atrial Appendage Closure
Q38631033	Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.
Q35683869	Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
Q37215041	Current and future management of pediatric venous thromboembolism
Q38134680	Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients.
Q37990564	Current anticoagulant safety
Q44739550	Current approaches to anticoagulation for reducing risk of atrial fibrillation-related stroke
Q38675822	Current challenges and future prospects in oral anticoagulant therapy
Q37960511	Current challenges in personalizing warfarin therapy
Q37774894	Current issues in antiplatelet therapy for stroke prevention: the importance of stroke subtypes and differences between stroke and MI patients
Q36072140	Current issues in atrial fibrillation
Q33755738	Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism
Q38826145	Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants
Q38108527	Current state of knowledge on oral anticoagulant reversal using procoagulant factors
Q92707388	Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study
Q37140198	Current strategies to minimize the bleeding risk of warfarin
Q38965647	Current treatment of heart failure with reduction of left ventricular ejection fraction
Q89776907	Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis
Q38647793	Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry
Q28070132	DOACs - advances and limitations in real world
Q64116802	DOACs vs Vitamin K Antagonists: a Comparison of Phase III Clinical Trials and a Prescriber Support Tool
Q39873589	DVT: a new era in anticoagulant therapy
Q36841028	Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.
Q55177633	Dabigatran Added to Dual Antiplatelet Therapy to Treat a Left Ventricular Thrombus in an 87 Year Old Patient With Myocardial Infarction and Very High Bleeding Risk.
Q42218549	Dabigatran Associated Leukocytoclastic Vasculitis
Q36255794	Dabigatran Effect on Left Ventricular Thrombus in a Patient with Acute Ischemic Stroke
Q39129273	Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation
Q42036878	Dabigatran Inhibits Staphylococcus aureus Coagulase Activity
Q88599269	Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences
Q41564106	Dabigatran Therapy Resulting in the Resolution of Rivaroxaban-resistant Left Atrial Appendage Thrombi in Patients with Atrial Fibrillation
Q64977002	Dabigatran Toxicity in Acute Kidney Injury: Hemodialysis and Idarucizumab Required.
Q38169616	Dabigatran Use in the Real World: A Multihospital System Experience
Q93023765	Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities
Q48608828	Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey
Q36267254	Dabigatran abrogates brain endothelial cell permeability in response to thrombin
Q43082536	Dabigatran and apolipoprotein B.
Q38122675	Dabigatran and kidney disease: a bad combination
Q38014343	Dabigatran and left atrial appendage thrombus.
Q87430343	Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors
Q86542608	Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs
Q35187005	Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis
Q38671030	Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
Q38193882	Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence: Case report with literature review
Q26744261	Dabigatran approaching the realm of heparin-induced thrombocytopenia
Q61455768	Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report
Q45155549	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Q48364320	Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong
Q42830264	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial
Q51219498	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
Q48889301	Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring.
Q36791747	Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.
Q64118635	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
Q46176054	Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study
Q58375646	Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation
Q52812029	Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation.
Q42703484	Dabigatran etexilate
Q39404447	Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
Q38218292	Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.
Q37715510	Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry
Q44699178	Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary
Q38193599	Dabigatran etexilate for venous thromboembolism: a safety evaluation
Q51039974	Dabigatran etexilate in a vitamin-K antagonist non responder patient during Heartware HVAD support.
Q51527745	Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
Q37961830	Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness
Q41812796	Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice
Q35485247	Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
Q37743508	Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation
Q28244905	Dabigatran etexilate: A novel oral direct thrombin inhibitor
Q37871725	Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease
Q38021821	Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation
Q37858373	Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
Q37832237	Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation
Q38255703	Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence
Q43042717	Dabigatran etexilate: advances in anticoagulation therapy
Q38821650	Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
Q35226978	Dabigatran etixilate and traumatic brain injury: Evolving anticoagulants require evolving care plans
Q38241091	Dabigatran excess: case report and review of the literature
Q42113819	Dabigatran exhibits low intensity of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation as compared with warfarin
Q40865343	Dabigatran for mechanical valves
Q37427004	Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies
Q58375684	Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial
Q35975334	Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions
Q38406325	Dabigatran for the prevention and treatment of thromboembolic disorders
Q38101892	Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal
Q38537977	Dabigatran for the treatment of venous thromboembolism
Q42042565	Dabigatran in atrial fibrillation: New kid on the block
Q42830259	Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk
Q84474916	Dabigatran in atrial fibrillation: pharmacology and clinical trials
Q36025096	Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management.
Q34009254	Dabigatran in secondary stroke prevention: clinical experience with 106 patients.
Q36784032	Dabigatran in the Treatment of Warfarin-Induced Skin Necrosis: A New Hope.
Q52932541	Dabigatran in the management of livedoid vasculopathy.
Q37083546	Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay
Q37679709	Dabigatran induced hemorrhagic cystitis in a patient with painful bladder syndrome
Q40609930	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation
Q64907706	Dabigatran must be used carefully: literature review and recommendations for management of adverse events.
Q34262668	Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial
Q53832048	Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study.
Q38744436	Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner.
Q41610947	Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.
Q34343069	Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study
Q33398934	Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies
Q39293580	Dabigatran use in mechanical heart valve patients
Q37731381	Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: protocol.
Q44690504	Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation
Q41103227	Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients
Q50860323	Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation.
Q34834319	Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model
Q38376637	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study
Q37115353	Dabigatran, A Direct Thrombin Inhibitor, In Atrial Fibrillation: Is It Already Time For A Change In Oral Anticoagulation Therapy?
Q21284803	Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
Q26783457	Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience
Q47142233	Dabigatran-Induced Spontaneous Hemopericardium and Cardiac Tamponade
Q86158062	Dabigatran-associated spontaneous acute cervical epidural hematoma
Q41648493	Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics.
Q84690636	Dabigatran-induced rash
Q37776610	Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
Q84319596	Dabigatran: a new anticoagulant for stroke prevention in patients with atrial fibrillation
Q44783204	Dabigatran: a new therapeutic alternative in the prevention of stroke
Q38020658	Dabigatran: a primer for neurosurgeons
Q37870757	Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation
Q37990337	Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.
Q38106833	Dabigatran: is there a role for coagulation assays in guiding therapy?
Q34196100	Dabigatran: patient management in specific clinical settings
Q36548878	Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant
Q38247017	Decade in review--arrhythmias: Cardiac fibrillation--challenges and evolving solutions
Q35122237	Decade-long trends in atrial fibrillation incidence and survival: a community study
Q40991109	Decennial Analysis of Interventional Left Atrial Appendage Closure
Q47431685	Deciphering Conformational Changes Associated with the Maturation of Thrombin Anion Binding Exosite I.
Q47686273	Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: A Practical Guide for Neurologists.
Q37672517	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor
Q36336046	Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.
Q49332595	Deep vein thrombosis: pathogenesis, diagnosis, and medical management.
Q47148139	Defibrillation Testing During ICD Implantation - Should we or Should we Not?
Q83554163	Defining innovations of therapeutic interventions: a position paper by the Italian Society of Hospital Pharmacists
Q38695989	Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.
Q48260874	Dental implant surgery in patients in treatment by dabigatran.
Q58694656	Dental management of patients on anti-thrombotic agents
Q36283736	Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran
Q50045818	Dental treatment in the era of new anti-thrombotic agents.
Q37412869	Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fi
Q64123344	Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism
Q57625963	Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study
Q40485244	Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-S
Q30249817	Detecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke
Q37866143	Detection of atrial fibrillation and secondary stroke prevention using telemetry and ambulatory cardiac monitoring.
Q35848816	Developing alerting thresholds for prospective drug safety monitoring.
Q40969950	Development of New Deep Venous Thrombosis While on Apixaban.
Q34658856	Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
Q64237396	Device-Related Thrombus: A Reason for Concern?
Q59808766	Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes
Q36528473	Diabetes and stroke prevention: a review
Q92783316	Diagnosis and Management of Left Atrium Appendage Thrombosis in Atrial Fibrillation Patients Undergoing Cardioversion
Q38240583	Diagnosis and management of atrial fibrillation: an overview.
Q55026261	Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants.
Q35966775	Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation
Q87383611	Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin
Q92027241	Differences in outcomes between oral anticoagulation "new starters" and "switchers" in patients with nonvalvular atrial fibrillation: A pooled analysis of the AMADEUS and BOREALIS trials
Q26799710	Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran
Q37636986	Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Q31070556	Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data
Q61807914	Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation
Q47972879	Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions.
Q41286371	Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System.
Q38998378	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature
Q38578564	Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism
Q53652929	Direct Oral Anticoagulants for Very Elderly People With Atrial Fibrillation: Efficacy and Safe Enough?
Q38575711	Direct Oral Anticoagulants for the Management of Thromboembolic Disorders: The Importance of Adherence and Persistence in Achieving Beneficial Outcomes
Q26787046	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities
Q47741252	Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.
Q30277086	Direct Oral Anticoagulants in Cirrhosis.
Q38961751	Direct Oral Anticoagulants in Emergency Trauma Admissions.
Q92988338	Direct Oral Anticoagulants: A Quick Guide
Q56003308	Direct Thrombin Inhibitors
Q55692305	Direct acting oral anticoagulant: Bench to bedside.
Q30595943	Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients
Q89284790	Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
Q38631413	Direct factor Xa inhibitor edoxaban: from bench to clinical practice
Q37447011	Direct new oral anticoagulants: follow-up, guidelines and bleeding complications in general practice-a survey of Swiss general internal medicine practitioners
Q48101005	Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis
Q50207168	Direct oral anticoagulant and antiplatelet combination therapy: Hemorrhagic events in coronary artery stent recipients.
Q39012313	Direct oral anticoagulant considerations in solid organ transplantation: A review
Q50123510	Direct oral anticoagulant reversal: how, when and issues faced.
Q40624080	Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation
Q28071807	Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review
Q39031152	Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation.
Q47103245	Direct oral anticoagulants and its implications in dentistry. A review of literature
Q96690761	Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus
Q38830527	Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients
Q92648688	Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
Q35689817	Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No.
Q30979197	Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes.
Q28079930	Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age
Q38707885	Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations
Q38415536	Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation
Q90299348	Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis
Q64898101	Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation.
Q47654635	Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Q52659269	Direct oral anticoagulants versus warfarin: is new always better than the old?
Q90071335	Direct oral anticoagulants: a review on the current role and scope of reversal agents
Q38228212	Direct oral anticoagulants: integration into clinical practice
Q35746798	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation
Q38893463	Direct oral anticoagulants: unique properties and practical approaches to management
Q38087189	Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation
Q24200617	Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation
Q94337721	Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation
Q37979872	Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease
Q38006641	Direct thrombin inhibitors in cardiovascular disease
Q24202488	Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with non-valvular atrial fibrillation
Q24197843	Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation
Q48299604	Direct thrombin inhibitors' potential efficacy in Alzheimer's disease
Q26746917	Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians
Q91771208	Direct-acting Oral Anticoagulants: An Overview
Q88035832	Direct-acting oral anticoagulant drug level monitoring in clinical patient management
Q34670808	Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.
Q91639992	Disappearance of an anticoagulation-resistant left atrial appendage thrombus after administration of low-dose pimobendan
Q55032516	Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
Q35177353	Discovery methodology for the development of direct factor VIIa inhibitors.
Q39766399	Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy
Q35893685	Discrepancies between Patients' Preferences and Educational Programs on Oral Anticoagulant Therapy: A Survey in Community Pharmacies and Hospital Consultations
Q38664199	Dissection of Cervical and Cerebral Arteries
Q59637718	Do Anticoagulants or Antiplatelet Drugs Have a Role in Treating Heart Failure in the Absence of Atrial Fibrillation?
Q41289704	Do CHA2 DS2 VASc and HAS-BLED scores influence 'real-world' anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre.
Q45042446	Do the current atrial fibrillation guidelines for stroke prevention need to be changed with the availability of new data on the new oral anticoagulants?
Q37442492	Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation?
Q43188575	Does dabigatran improve stroke prevention in atrial fibrillation? A rebuttal
Q55053760	Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai.
Q42409317	Does the FDA Owe Us an Explanation?
Q38025674	Does the STAF score help detect paroxysmal atrial fibrillation in acute stroke patients?
Q58574436	Dosing challenges with direct oral anticoagulants in the elderly: a retrospective analysis
Q38535649	Dosing of Target-Specific Oral Anticoagulants in Special Populations
Q38101068	Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital
Q37933420	Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series
Q26741058	Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel
Q34255442	Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
Q62581028	Dronedarone
Q38902986	Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey.
Q95846773	Drug Dosing Recommendations for All Patients: A Roadmap for Change
Q38902415	Drug Interactions of Direct-Acting Oral Anticoagulants
Q37848142	Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
Q38616215	Drug interactions with new oral anticoagulants in elderly patients
Q35239819	Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry
Q53925224	Drug therapy in anticoagulation: which drug for which patient?
Q36305013	Drug therapy in atrial fibrillation management: where do we stand in 2010?
Q37342995	Drug treatment of acute ischemic stroke
Q90211829	Drug-Drug Interactions with Direct Oral Anticoagulants
Q38830358	Drug-drug interactions of non-vitamin K oral anticoagulants
Q34284224	Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term
Q48765791	During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time.
Q43837028	Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study
Q34651036	EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
Q38821168	ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
Q40156592	EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology.
Q38367743	Early Anti-Coagulation after Ischemic Stroke due to Atrial Fibrillation is Safe and Prevents Recurrent Stroke
Q49197579	Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
Q37457554	Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation
Q93334631	Early dabigatran treatment after transient ischemic attack and minor ischemic stroke does not result in hemorrhagic transformation
Q35648223	Early experience using a left atrial appendage occlusion device in patients with atrial fibrillation
Q37737560	Early management of atrial fibrillation: from imaging to drugs to ablation
Q41159297	Early operative comparison of two epicardial left atrial appendage occluding systems applied during off-pump coronary revascularisation in patients with persistent atrial fibrillation
Q37312543	Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care
Q35915270	Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium
Q57130338	Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
Q59391751	Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study.
Q34004770	Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands
Q33651588	Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation
Q53777211	Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for pati
Q86924935	Edoxaban and the need for outcomes-based NOAC dosing
Q48195435	Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper
Q37699699	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.
Q33793622	Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons
Q38525918	Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view
Q26751263	Edoxaban in venous thromboembolism and stroke prevention: an appraisal
Q92507410	Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
Q53507298	Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.
Q38412381	Edoxaban, a Novel Oral Factor Xa Inhibitor
Q39103395	Edoxaban: A direct oral anticoagulant
Q84810467	Edoxaban: a new oral direct factor xa inhibitor
Q33935409	Edoxaban: an update on the new oral direct factor Xa inhibitor
Q37907319	Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
Q93055494	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial
Q24202280	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Q36335405	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.
Q36714127	Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
Q37575117	Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
Q38779508	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect
Q55031739	Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer.
Q37576987	Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin
Q48124599	Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection
Q39041702	Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs).
Q34233473	Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation
Q35225444	Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users
Q50790883	Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
Q38409730	Effective practical management of patients with atrial fibrillation when using new oral anticoagulants
Q37076243	Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
Q64980707	Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies.
Q64063492	Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
Q89532369	Effectiveness and Safety of Off-label Dosing of Non-vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients
Q64119437	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients
Q96118067	Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study
Q38725712	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Q93036462	Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation
Q89544746	Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients
Q36085794	Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study
Q37222352	Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation
Q33552976	Effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with atrial fibrillation: A single-center observational study
Q65000752	Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Q93035382	Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: A systematic review and meta-analysis
Q64123131	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation
Q64119538	Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia
Q33647367	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Q58562887	Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation
Q42676634	Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate pres
Q64072446	Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis
Q36472678	Effectiveness of structured, hospital-based, nurse-led atrial fibrillation clinics: a comparison between a real-world population and a clinical trial population.
Q38673244	Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis
Q57180613	Effects of a reminder to initiate oral anticoagulation in patients with atrial fibrillation/atrial flutter discharged from the emergency department: REMINDER study
Q82417679	Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke
Q89818018	Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth
Q38951011	Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal
Q39300348	Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis
Q53160398	Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate.
Q37115151	Efficacy And Safety of Dabigatran Etexilate Utilization With Concomitant Dual Antiplatelet Therapy In Atrial Fibrillation
Q28085676	Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis
Q52603891	Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
Q92135827	Efficacy and Safety of Direct Oral Anticoagulants in Elderly Patients With Atrial Fibrillation: A Network Meta-Analysis
Q90680256	Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and High Thromboembolic Risk. A Systematic Review
Q96303752	Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese
Q58130065	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study
Q35631782	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis
Q94672595	Efficacy and Safety of Non-Vitamin K Anticoagulants for Atrial Fibrillation in Relation to Different Renal Function Levels: A Network Meta-Analysis
Q36999959	Efficacy and Safety of Novel Oral Anticoagulants for Atrial Fibrillation Ablation: An Updated Meta-Analysis
Q38952056	Efficacy and Safety of the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Chinese Patients with Nonvalvular Atrial Fibrillation: A Single-center, Prospective, Observational Study
Q41108701	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial
Q53122745	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Q53667550	Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
Q34134664	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
Q50867082	Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.
Q90299294	Efficacy and safety of dabigatran versus warfarin from the RE-LY trial
Q40454302	Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project.
Q55065699	Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.
Q92323366	Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
Q40597502	Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials.
Q42368581	Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
Q42017822	Efficacy and safety of novel anticoagulants compared with established agents.
Q28079383	Efficacy and safety of novel anticoagulants in the elderly
Q34694471	Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden
Q48945274	Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves.
Q37623666	Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Q38386998	Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
Q36321564	Efficacy and safety of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-analysis
Q37649893	Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence
Q33589886	Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.
Q45285359	Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial.
Q26749141	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
Q92284658	Elderly Bleeding Risk of Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Cohort Studies
Q37240792	Electronic Alert System for Improving Stroke Prevention Among Hospitalized Oral-Anticoagulation-Naïve Patients With Atrial Fibrillation: A Randomized Trial
Q37345208	Electrophysiology and heart rhythm disorders in older adults
Q44447737	Embolic strokes of undetermined source: the case for a new clinical construct
Q38223609	Emergency reversal of anticoagulation: novel agents
Q35578443	Emergency reversal of dabigatran for emergency surgery.
Q26743614	Emergent Bleeding in Patients Receiving Direct Oral Anticoagulants
Q26765023	Emerging Tools for Stroke Prevention in Atrial Fibrillation
Q37847175	Emerging anticoagulants
Q37755889	Emerging anticoagulants for venous thromboembolism prevention
Q37827882	Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises
Q37949587	Emerging therapies for acute coronary syndromes
Q51842414	Emerging therapies for atrial fibrillation: is the paradigm shifting?
Q33721188	Empirical anticoagulation for patients in sinus rhythm at high risk of ischaemic stroke: A review of current literature
Q36682317	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines
Q35210137	Enhanced elimination of dabigatran through extracorporeal methods.
Q50755547	Epicardial clip occlusion of the left atrial appendage during cardiac surgery provides optimal surgical results and long-term stability.
Q42696103	Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery.
Q97905343	Epidemiology and treatment of atrial fibrillation in patients with type 2 diabetes in the UK, 2001-2016
Q36266774	Epidemiology of Intracranial Haemorrhages Associated with Vitamin K Antagonist Oral Anticoagulants in Spain: TAC Registry
Q88684953	Epidemiology of Intracranial Hemorrhage Associated with Oral Anticoagulants in Spain: Trends in Anticoagulation Complications Registry - The TAC 2 Study
Q28083655	Epidemiology, diagnosis, and management of atrial fibrillation in women
Q84517837	Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance
Q33714864	Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation
Q51737541	Estimated glomerular filtration ratio is a better index than creatinine clearance (Cockcroft-Gault) for predicting the prevalence of atrial fibrillation in the general Japanese population.
Q63242297	Estimating renal function in patients with atrial fibrillation: which dose of direct oral anticoagulants?
Q61804279	Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective
Q38183305	Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials
Q98161485	Ethnic Differences in Oral Antithrombotic Therapy
Q33591111	Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans
Q38007885	Etiologies of intracerebral hematomas
Q85322524	Etiology and treatment of arterial ischemic stroke in children and young adults
Q51176715	EuroThrombosis: annual meeting of the European Society of Cardiology Working Group on Thrombosis.
Q34651051	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
Q36617346	European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care.
Q37017398	European research priorities for intracerebral haemorrhage
Q38608242	Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants
Q35966238	Evaluating the Initiation of Novel Oral Anticoagulants in Medicare Beneficiaries.
Q91015721	Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making
Q28079137	Evaluating the benefits of home-based management of atrial fibrillation: current perspectives
Q36342841	Evaluating the effectiveness of risk minimisation measures: the application of a conceptual framework to Danish real-world dabigatran data
Q42790797	Evaluating the impact of new anticoagulants in the hospital setting.
Q91952328	EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non-valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study
Q40867348	Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy
Q91598526	Evaluation of Dabigatran vs Warfarin Before Cardioversion of Atrial Arrhythmias
Q35475000	Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age
Q55371809	Evaluation of Dosing Practices of Rivaroxaban and Dabigatran.
Q52654889	Evaluation of a protocol for early detection of delayed brain hemorrhage in head injured patients on warfarin.
Q38598970	Evaluation of bleeding in patients receiving direct oral anticoagulants
Q44284239	Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval.
Q34720391	Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting
Q50751291	Evaluation of dabigatran utilization and risk among hospitalized patients.
Q40108865	Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar
Q46214569	Evaluation of pharmacist-managed dabigatran in an inpatient setting
Q51368043	Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Q41627248	Evaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis System®: In Vitro and Ex Vivo Studies
Q58772750	Evaluation of the Bleeding Intensity of Patients Anticoagulated with Warfarin or Dabigatran Undergoing Dental Procedures
Q38233775	Evaluation of the WATCHMAN left atrial appendage closure device
Q51284466	Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation Analysis System®.
Q36875879	Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting
Q38946563	Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
Q47797204	Evaluation of the predictive performance of bleeding risk scores in patients with non-valvular atrial fibrillation on oral anticoagulants
Q37203311	Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trial
Q34967540	Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study
Q49647319	Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants.
Q38136147	Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation
Q47110069	Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis
Q27023274	Evidence for the prevention and treatment of stroke in dialysis patients
Q91649347	Evidence-Practice Gaps in Postdischarge Initiation With Oral Anticoagulants in Patients With Atrial Fibrillation
Q36087921	Evidence-based percutaneous closure of the left atrial appendage in patients with atrial fibrillation
Q43487404	Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists.
Q91787892	Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting
Q34047821	Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Q36176607	Exclusion of the left atrial appendage to prevent stroke in cases of atrial fibrillation
Q30101004	Executive Summary of the II Brazilian Guidelines for Atrial Fibrillation
Q92381964	Experience of left atrial appendage occlusion with the WATCHMAN device in Chinese patients
Q37859771	Expert opinion on emerging drugs in childhood arterial ischemic stroke
Q26998331	Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
Q42433032	Explaining the RE-LY Trial.
Q36112764	Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect
Q41495478	Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding
Q92060697	Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation
Q46989883	Expression of protease activated receptor-1 in chronic periodontitis.
Q37932628	External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?
Q37246953	Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience
Q36146850	FDA drug safety communications: a narrative review and clinical considerations for older adults
Q83067930	Factor Xa and thrombin as targets for new oral anticoagulants
Q38903357	Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants
Q61797763	Factors affecting general practitioners' decisions to adopt new prescription drugs - cohort analyses using Australian longitudinal physician survey data
Q40063914	Factors associated with 'caregiver burden' for atrial fibrillation patients
Q39567501	Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia
Q40140300	Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs.
Q47213606	Factors associated with availability of anticoagulation reversal agents in rural and community emergency departments.
Q34388959	Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
Q35235448	Factors driving anticoagulant selection in patients with atrial fibrillation in the United States.
Q43066406	Factors in Deciding between Novel and Traditional Oral Anticoagulants to Prevent Embolism in Atrial Fibrillation Patients
Q46064436	Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation
Q35982946	Fast atrial fibrillation and caecal volvulus--a case report and evidence based management
Q53167127	Fast point-of-care coagulometer guided reversal of oral anticoagulation at the bedside hastens management of acute subdural hemorrhage.
Q43876841	Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity.
Q53132050	Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Q87306258	Fatal dabigatran-associated bleeding
Q50506834	Fatal gastrointestinal hemorrhage after a single dose of dabigatran.
Q33889600	Feasibility of TEE-guided stroke risk assessment in atrial fibrillation-background, aims, design and baseline data of the TIARA pilot study
Q93377044	Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia
Q44176213	Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis
Q38900011	Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin
Q47935786	Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial
Q39146511	Financial Impact of Direct-Acting Oral Anticoagulants in Medicaid: Budgetary Assessment Based on Number Needed to Treat
Q37581151	Five years of keeping a watch on the left atrial appendage-how has the WATCHMAN fared?
Q41772020	For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding
Q33579584	Forecasting drug utilization and expenditure in a metropolitan health region
Q38197728	Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal
Q88766089	Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices
Q89919577	Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation
Q38675421	Free Fatty Acid Is Associated with Thrombogenicity in Cardioembolic Stroke
Q49913783	Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Q33847039	Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillation
Q57796944	Frequency of atrial thrombus formation in patients with atrial fibrillation under treatment with non-vitamin K oral anticoagulants in comparison to vitamin K antagonists: a systematic review and meta-analysis
Q39683385	Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial
Q37822915	Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
Q37772194	Future of anticoagulant therapy
Q88404761	GI Bleeding Risk of DOACs Versus Warfarin: Is Newer Better?
Q46767113	Gastrointestinal bleeding associated with dabigatran in a patient with panhypopituitarism.
Q39217774	Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Q34409701	Gastrointestinal comorbidities associated with atrial fibrillation
Q38041636	Gastrointestinal disorders and dabigatran
Q90268364	Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes
Q26765963	Gender Differences of Thromboembolic Events in Atrial Fibrillation
Q38155124	Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention
Q39193538	Gender differences in the effects of cardiovascular drugs
Q55007371	Gender-related Differences in Management of Nonvalvular Atrial Fibrillation in an Asian Population.
Q37963892	Gene-drug interaction in stroke
Q38652739	General Medical Considerations for the Wilderness Adventurer: Medical Conditions That May Worsen With or Present Challenges to Coping With Wilderness Exposure.
Q27316270	Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner
Q40637492	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy
Q49142379	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Q90414679	Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE-AF
Q36354208	Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran
Q92475983	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis
Q89448115	Global research productions pertaining to atrial fibrillation from 2004 to 2018: A bibliometric analysis
Q90194837	Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation
Q50974157	Graphical representation of life paths to better convey results of decision models to patients.
Q28076077	Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Q28078989	Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Q33863833	Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group
Q38682353	Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
Q92994476	Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D
Q22306331	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Q22306361	Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Q42923039	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
Q37251490	Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association
Q33815633	HRS policy statement: clinical cardiac electrophysiology fellowship curriculum: update 2011
Q37640881	Haemorrhagic Transformation after Ischaemic Stroke in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants
Q48371887	Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways
Q50899846	Haemostasis biomarkers and risk of intracerebral haemorrhage in the REasons for Geographic and Racial Differences in Stroke Study.
Q36021214	Health technology assessment and its role in the future development of the Indian healthcare sector
Q51007969	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
Q33823354	Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Q90656095	Heart Failure and Stroke
Q55008079	Heart Failure as a Risk Factor for Stroke.
Q38920727	Heart Rhythm Society: expert consensus statements-part 2.
Q35138993	Heart failure and atrial fibrillation: from basic science to clinical practice
Q36023804	Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection
Q38734794	Hematoma Expansion following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation.
Q89205672	Hemodialysis for removal of dabigatran in a patient with gastric hemorrhage
Q38566089	Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review.
Q36485029	Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate
Q57643995	Hemopericardium in a patient treated with dabigatran etexilate
Q41845997	Hemoperitoneum secondary to intercostal arterial bleeding in a trauma patient
Q33403265	Hemorrhagic complications associated with dabigatran use.
Q61314461	Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA)
Q33842161	Hemostasis and alterations of the central nervous system
Q41729767	Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis
Q38786754	Hierarchical Models for Multiple, Rare Outcomes Using Massive Observational Healthcare Databases
Q47805989	High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy
Q38844348	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting
Q27678539	High-resolution crystal structures of factor XIa coagulation factor in complex with nonbasic high-affinity synthetic inhibitors
Q53178956	Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil.
Q51035409	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
Q50956895	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil.
Q47268269	Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil
Q53838560	Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil.
Q37859745	Highlights of the latest clinical trials from the 2010 Scientific Sessions of the American Heart Association
Q37903961	Historical perspective and future direction of coagulation research
Q38646281	Home medicines reviews in Australian war veterans taking warfarin do not influence international normalised ratio control
Q92481798	Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban
Q52670897	Hospital and clinical care costs associated with atrial fibrillation for Medicare beneficiaries in the Cardiovascular Health Study and the Framingham Heart Study.
Q51168958	Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service.
Q37924500	Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice
Q43650765	Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome
Q30573351	Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more
Q44539773	Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011.
Q33506115	Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more
Q46903604	How To Manage Oral Anticoagulation Periprocedurally During Ablations And Device Implantations
Q35028969	How confidence intervals become confusion intervals
Q57914440	How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ?
Q40218370	How do family medicine residents choose an anticoagulation regimen for patients with nonvalvular atrial fibrillation?
Q36021753	How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
Q26776413	How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation
Q53120189	How to manage antiplatelet therapy for stenting in a patient requiring oral anticoagulants.
Q37903951	How to prevent, treat, and overcome current clinical challenges of VTE.
Q26748343	How we treat bleeding associated with direct oral anticoagulants
Q33875897	Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants
Q47775639	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoam
Q42339767	Idarucizumab (Praxbind) for reversal of pradaxa prior to emergent repair of contained ruptured transverse arch aneurysm
Q90173780	Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study
Q90300280	Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation
Q39448172	Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.
Q38624595	Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence
Q38740620	Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran
Q48131769	Identification and management of noncompliance in atrial fibrillation patients receiving dabigatran: the role of a drug monitor
Q37550678	Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis
Q38984971	Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants.
Q35070620	Identifying future research priorities using value of information analyses: left atrial appendage occlusion devices in atrial fibrillation
Q37860968	Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update.
Q37203620	Identifying the risks of anticoagulation in patients with substance abuse
Q39914418	Idraparinux and idrabiotaparinux.
Q37701367	Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography
Q64086854	Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke
Q36518566	Impact of CHADS(2) Score on Neurological Severity and Long-Term Outcome in Atrial Fibrillation-Related Ischemic Stroke
Q35851558	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).
Q89807080	Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
Q47800785	Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective
Q37589203	Impact of Pharmacists' audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study
Q35806598	Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study.
Q61809445	Impact of atrial fibrillation on in-hospital mortality of ischemic stroke patients and identification of promoting factors of atrial thrombi - Results from the German nationwide inpatient sample and a single-center retrospective cohort
Q64951862	Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center.
Q34343826	Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis
Q37653118	Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter
Q34633608	Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial
Q30315374	Impact of periprocedural anticoagulation strategy on the incidence of new-onset silent cerebral events after radiofrequency catheter ablation of atrial fibrillation.
Q87866410	Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke
Q33949432	Impact of prescribed medications on patient safety in older people
Q41480605	Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Q34087971	Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians.
Q30371014	Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation.
Q38384634	Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study
Q50553670	Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study.
Q30994474	Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data
Q35794636	Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients
Q38001974	Implementing the new oral anticoagulants into the hospital formulary
Q38819152	Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice
Q38073006	Implications of new anticoagulants in primary practice
Q48795541	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy.
Q26766094	Improved Cardiovascular Disease Outcomes in Older Adults
Q43554121	Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method.
Q50983525	Improved oral bioavailability and therapeutic efficacy of dabigatran etexilate via Soluplus-TPGS binary mixed micelles system.
Q47256358	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
Q36801214	Improving anticoagulation management in patients with atrial fibrillation
Q36367834	Improving postapproval drug safety surveillance: getting better information sooner
Q45924410	In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
Q64067114	In-Hospital Bleeding Outcomes of Myocardial Infarction in the Era of Warfarin and Direct Oral Anticoagulants for Atrial Fibrillation in the United States: A Report From the National Cardiovascular Data Registry Acute Coronary Treatment and Interventi
Q55506183	In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation.
Q37680357	Inappropriate combination of warfarin and aspirin
Q47571622	Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.
Q47168624	Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation
Q92866782	Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
Q90224915	Incidence and Predictors of Intracardiac Thrombus on Pre-electrophysiological Procedure Transesophageal Echocardiography
Q55105150	Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation.
Q37900217	Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment
Q42368314	Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
Q94661279	Incidence of Direct Oral Anticoagulant Prescriptions in Kidney Transplant Recipients in Ontario, Canada
Q88669205	Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset
Q39267912	Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation
Q37355781	Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists
Q40324251	Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants
Q47291952	Incidence of thromboembolic and bleeding events in patients with newly diagnosed nonvalvular atrial fibrillation: An Asian multicenter retrospective cohort study in Singapore
Q35575180	Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy
Q35115116	Incidence, mortality, and sex differences of non-valvular atrial fibrillation: a population-based study
Q37862925	Incidental atrial fibrillation and its management
Q99406821	Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality
Q38904529	Incomplete Closure of the Left Atrial Appendage: Implication and Management
Q39449914	Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics
Q33698353	Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial
Q35755253	Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy
Q50574389	Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark.
Q41433678	Increasing rate of atrial fibrillation from 2003 to 2011 in patients with ischaemic stroke: results from 55,551 patients in a nationwide registry
Q89795581	Increasing use of anticoagulants in Germany and its impact on hospitalization rates for genitourinary bleeding
Q42244714	Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients
Q37235927	Individualising Anticoagulant Therapy in Atrial Fibrillation Patients
Q36253510	Inflammation and hemostasis in atrial fibrillation and coronary heart disease: The REasons for Geographic And Racial Differences in Stroke study
Q40903055	Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery
Q57061842	Influence of peer networks on physician adoption of new drugs
Q47132139	Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation
Q38224507	Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis
Q47547608	Influence of stroke and bleeding risk on prescribing of oral anticoagulants in older inpatients; has the availability of direct oral anticoagulants changed prescribing?
Q38799910	Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients
Q34410830	Initial 3-weeks' Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) followed by Clopidogrel alone in high-risk patients with Acute Non-Disabling Cerebrovascular Events (ADANCE): study protocol for a randomized controlled trial
Q51739901	Initial Apixaban Dosing in Patients with Atrial Fibrillation.
Q51685827	Initial Experience With Novel Oral Anticoagulants During the First 45 Days After Left Atrial Appendage Closure With the Watchman Device.
Q38081938	Initial and long-term treatment of deep venous thrombosis: recent clinical trials and their impact on patient management.
Q39359007	Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?
Q38799019	Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?
Q36264914	Innovative designs of point-of-care comparative effectiveness trials
Q43182889	Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial
Q39889806	Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).
Q47883450	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference
Q38768207	Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review
Q56979792	Interactions between cardiovascular and cerebrovascular disease
Q53551807	Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.
Q40556792	Intermittent vs. Continuous Anticoagulation theRapy in patiEnts with Atrial Fibrillation (iCARE-AF): a randomized pilot study
Q64091392	International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
Q34688742	Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.
Q34040279	Intersection of cardiovascular disease and kidney disease: atrial fibrillation
Q38630969	Interventional and surgical occlusion of the left atrial appendage
Q45764026	Interventional left atrial appendage occlusion : alternative to oral anticoagulation for stroke prevention in atrial fibrillation
Q52641190	Interventions and Strategies to Improve Oral Anticoagulant Use in Patients with Atrial Fibrillation: A Systematic Review of Systematic Reviews.
Q58092864	Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review
Q42845067	Intra-cardiac thrombus resolution after anti-coagulation therapy with dabigatran in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy: a case report
Q36984232	Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies
Q43574054	Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study
Q38113483	Intracerebral hemorrhage in patients receiving oral anticoagulation therapy
Q38035818	Intracerebral hemorrhage: a review of coagulation function.
Q39962487	Intracranial Hemorrhage Risk in the Era of Antithrombotic Therapies for Ischemic Stroke
Q26825331	Intracranial hemorrhage
Q82946736	Intracranial hemorrhage
Q38197124	Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned?
Q37479416	Intracranial hemorrhage during administration of a novel oral anticoagulant
Q33977604	Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin
Q35224171	Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis
Q30377553	Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report.
Q54757920	Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model.
Q37399567	Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report
Q48806105	Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.
Q90679647	Introduction of Non-Vitamin K Antagonist Anticoagulants Strongly Increased the Rate of Anticoagulation in Hospitalized Geriatric Patients with Atrial Fibrillation
Q89122086	Introduction of direct oral anticoagulant within 7 days of stroke onset: a nomogram to predict the probability of 3-month modified Rankin Scale score > 2
Q37115686	Invasive Management of Atrial Fibrillation and the Elderly
Q38594609	Investigational new drugs for the treatment of acute coronary syndrome
Q91130357	Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management
Q38132255	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation
Q36232280	Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide
Q38541307	Is dabigatran efficacy enough to prevent stroke in atrial fibrillation patient with high CHADS2 score during peri-procedural catheter radiofrequency ablation? A case report with literature review.
Q40896985	Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?
Q84590279	Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA?
Q88961925	Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stro
Q45878437	Is there a role for new oral anticoagulants as primary and secondary stroke prevention in atrial fibrillation and intracranial stenosis?
Q41520842	Is there an alternative treatment for patients intolerant to antiplatelet therapy if percutaneous left atrial appendage closure is considered?
Q53484741	Is thrombin time too sensitive to dabigatran anticoagulation for clinical decision making in the setting of acute hemorrhage?
Q39289650	Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study
Q37497560	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
Q90614578	Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation
Q56626172	Kommentar zu den Leitlinien der ESC zum Vorhofflimmern
Q57626913	Kommentar: Fokus Update der Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des Vorhofflimmerns
Q41686228	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.
Q89563788	LMU Munich: platelet inhibition novel aspects on platelet inhibition and function
Q34223524	LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin?
Q64230119	Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
Q96113830	Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation
Q38956699	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review
Q39041243	Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know
Q36162324	Laboratory evidence of disseminated intravascular coagulation is associated with a fatal outcome in children with cerebral malaria despite an absence of clinically evident thrombosis or bleeding
Q34206252	Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Q35698491	Lack of Association of Clinical Factors (SAMe-TT2R2) with CYP2C9/VKORC1 Genotype and Anticoagulation Control Quality
Q58130560	Large Left Ventricular Thrombus as a Cause of Recurrent Cardioembolic Stroke While on Dabigatran
Q41005621	Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation
Q44632015	Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010.
Q39540577	Learning Curve Assessment for Percutaneous Left Atrial Appendage Closure With the WATCHMAN Occluder
Q38233568	Leaving no hole unclosed: left atrial appendage occlusion in patients having closure of patent foramen ovale or atrial septal defect
Q51821631	Left Atrial Appendage Closure -The WATCHMAN Device.
Q95724841	Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment
Q34931005	Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?
Q47328033	Left Atrial Appendage Closure with Amplatzer Cardiac Plug in Nonvalvular Atrial Fibrillation: Safety and Long-Term Outcome
Q55041488	Left Atrial Appendage Closure – The WATCHMAN Device.
Q38790332	Left Atrial Appendage Occlusion for Stroke Prevention in Patients with Nonrheumatic Atrial Fibrillation
Q92312176	Left Atrial Appendage Transcatheter Occlusion with AMPLATZER™ Amulet™ Device: Real Life Data with Mid-Term Follow-Up Results
Q37496324	Left Atrial Thrombosis Despite Dabigatran Therapy
Q41065525	Left Atrial and Left Atrial Appendage 4D Blood Flow Dynamics in Atrial Fibrillation
Q37764740	Left atrial appendage closure
Q64228082	Left atrial appendage closure device implantation guided with fluoroscopy only: Long-term results
Q27001220	Left atrial appendage closure devices
Q92675026	Left atrial appendage closure in atrial fibrillation patients with prior major bleeding or ineligible for oral anticoagulation
Q37041648	Left atrial appendage closure in patients with atrial fibrillation in whom warfarin is contra-indicated: initial South African experience
Q34080391	Left atrial appendage closure to prevent stroke in patients with atrial fibrillation
Q94322527	Left atrial appendage closure versus oral anticoagulation for preventing stroke in people with atrial fibrillation
Q53459076	Left atrial appendage closure with amplatzer cardiac plug in atrial fibrillation: Initial european experience
Q37951277	Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation
Q39036222	Left atrial appendage closure: outcomes and challenges
Q30457989	Left atrial appendage devices for stroke prevention in atrial fibrillation
Q35691402	Left atrial appendage exclusion for atrial fibrillation
Q42369267	Left atrial appendage exclusion for atrial fibrillation: does the protection from stroke prevail in the long-term?
Q38177227	Left atrial appendage exclusion for prevention of stroke in atrial fibrillation: review of minimally invasive approaches
Q36344168	Left atrial appendage exclusion for stroke prevention in atrial fibrillation
Q41356789	Left atrial appendage occlusion for prevention of stroke in nonvalvular atrial fibrillation: a meta-analysis
Q38526411	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation
Q43417151	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: ready for the prime time?
Q37499401	Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage
Q39522391	Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation
Q83350381	Left atrial appendage occlusion in valvular atrial fibrillation following MitraClip implantation
Q37670952	Left atrial appendage occlusion: A better alternative to anticoagulation?
Q46562539	Left atrial flow velocity distribution and flow coherence using four-dimensional FLOW MRI: a pilot study investigating the impact of age and Pre- and Postintervention atrial fibrillation on atrial hemodynamics
Q41542222	Left ventricular endocardial pacing in cardiac resynchronisation therapy: Moving from bench to bedside
Q88923060	Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel
Q55090882	Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban.
Q126659203	Lenient versus Strict Rate Control in Atrial Fibrillation
Q48201953	Leveraging model-informed approaches for drug discovery and development in the cardiovascular space.
Q38511050	Limb ischemia: cardiovascular diagnosis and management from head to toe.
Q37310531	Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic
Q52628854	Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.
Q37827195	Lone atrial fibrillation: what is known and what is to come
Q30409016	Lone atrial fibrillation: where are we now?
Q64056026	Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry
Q36909458	Long-term anticoagulation in the extreme elderly with the newer antithrombotics: safe or sorry?
Q37052290	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation
Q39878127	Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience
Q86958630	Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents
Q48181457	Long-term stroke prevention: We can do better.
Q34926806	Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial
Q39064825	MEDEX South Carolina: a progress report
Q30673203	MRI screening for chronic anticoagulation in atrial fibrillation
Q38961671	Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients
Q92099458	Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors
Q34585334	Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies
Q37456586	Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States
Q50199880	Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Q38215953	Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
Q33552917	Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study).
Q39198562	Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events
Q38955911	Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs
Q38497702	Management and prognosis of atrial fibrillation in the diabetic patient.
Q37469045	Management of Atrial Fibrillation in Patients With Kidney Disease
Q51735257	Management of Atrial Fibrillation.
Q48375140	Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Q90419276	Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion
Q39307453	Management of Direct-Acting Oral Anticoagulants Surrounding Dental Procedures With Low-to-Moderate Risk of Bleeding
Q38961826	Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review
Q53715134	Management of Major Bleeding Related to Novel Oral Anticoagulant Agents Use in Frail Elderly Adults.
Q36412144	Management of Oral Anticoagulation Therapy After Gastrointestinal Bleeding: Whether to, When to, and How to Restart an Anticoagulation Therapy
Q95844794	Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide
Q38975409	Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association
Q26766303	Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy
Q34111320	Management of acute stroke in patients taking novel oral anticoagulants
Q51788589	Management of anticoagulation in hip fractures: A pragmatic approach.
Q26746160	Management of antithrombotic therapy during cardiac implantable device surgery
Q38364982	Management of antithrombotic therapy in patients undergoing electrophysiological device surgery
Q87752222	Management of atrial fibrillation
Q37895394	Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines
Q37556650	Management of atrial fibrillation in critically ill patients.
Q59612892	Management of atrial fibrillation in patients taking targeted cancer therapies
Q38369003	Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline?
Q38067326	Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?
Q38542430	Management of atrial fibrillation: recommendations from NICE.
Q38152888	Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations
Q40806195	Management of bleeding complications in patients with cancer on DOACs
Q38049617	Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach
Q26740258	Management of bleeding in patients treated with direct oral anticoagulants
Q38082646	Management of cardiovascular disease in patients with kidney disease
Q53624973	Management of dabigatran-induced bleeding with continuous venovenous hemodialysis.
Q37337581	Management of dabigatran-induced bleeding: expert statement
Q91851816	Management of epistaxis in patients on novel oral anticoagulation therapy
Q33803111	Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review
Q38254250	Management of hemorrhage with the target-specific oral anticoagulants
Q33400573	Management of heparin-induced thrombocytopenia.
Q30431467	Management of ischaemic stroke in the acute setting: review of the current status
Q56381361	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry
Q34207558	Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting
Q38429313	Management of oral anticoagulation in the surgical patient
Q43788136	Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry.
Q35167436	Management of patients with atrial fibrillation: specific considerations for the old age.
Q57183611	Management of patients with stroke treated with direct oral anticoagulants
Q37978469	Management of postoperative atrial fibrillation
Q37250616	Management of stroke prevention in canadian patients with atrial fibrillation at moderate to high risk of stroke.
Q38093286	Management of venous thromboembolism--controversies and the future
Q52811915	Management strategies for atrial fibrillation.
Q38175043	Management strategies in cardiac surgery for postoperative atrial fibrillation: contemporary prophylaxis and futuristic anticoagulant possibilities
Q42007287	Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report.
Q26991728	Managing anticoagulation for atrial fibrillation: current issues and future strategies
Q37659215	Managing atrial fibrillation in the global community: The European perspective
Q26775877	Managing atrial fibrillation in the very elderly patient: challenges and solutions
Q35900515	Managing atrial fibrillation.
Q50875752	Managing direct oral anticoagulants in patients undergoing dentoalveolar surgery.
Q34511297	Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications
Q88195712	Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation
Q39253985	Managing the perioperative patient on direct oral anticoagulants
Q90653409	Massive Left Atrial Thrombi during Dabigatran Therapy for Nonvalvular Atrial Fibrillation
Q37597998	Massive haemoptysis following dabigatran administration in a patient with bronchiectasis
Q36802843	Matching on the disease risk score in comparative effectiveness research of new treatments
Q85926737	Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study
Q35154142	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.
Q45865979	Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology
Q33795571	Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
Q45963327	Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.
Q38895665	Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?
Q38091327	Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations
Q38154476	Mechanical antithrombotic intervention by LAA occlusion in atrial fibrillation
Q33936082	Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks
Q35948292	Medical management of venous thromboembolism: what the interventional radiologist needs to know
Q37875489	Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke
Q55089049	Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect".
Q33777936	Medication errors involving anticoagulants: Data from the Danish patient safety database
Q35209970	Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention.
Q38741773	Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system.
Q49360165	Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome.
Q36015458	Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin
Q61800302	Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
Q97424452	Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach?
Q100415968	Midterm outcomes of LAA occlusion with the AMPLATZER Cardiac Plug and AMPLATZER Amulet devices in a high-risk cohort
Q28069809	Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention
Q38833382	Minimizing the Risk of Bleeding with NOACs in the Elderly
Q38389058	Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.
Q53156908	Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists.
Q61863356	Mise au point sur la prise en charge de la FA et prévention des AVC
Q42376565	Misleading Advertising by Attorneys Concerning NOACs is Adversely Costly to Our Patients and Our Society
Q36025087	Mixed cerebrovascular disease and the future of stroke prevention
Q47429080	Modelling projections for the risks related with atrial fibrillation in East Asia: a focus on ischaemic stroke and death
Q33715413	Modern role for clopidogrel in management of atrial fibrillation and stroke reduction
Q34788250	Modern treatment of atrial fibrillation
Q26771728	Monitoring anticoagulant therapy with new oral agents
Q87523227	Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation
Q37853075	Monitoring of direct anticoagulants
Q36458797	Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants
Q42620091	More indications approved and safety news for dabigatran etexilate
Q42875535	More or less irregularity in understanding an irregular rhythm: atrial fibrillation classification and racial differences
Q38650373	Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting System
Q38584212	Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials
Q34677974	Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation
Q92591385	Multicenter Study of the Hemorrhage Risk after Endoscopic Mucosal Resection Associated with Direct Oral Anticoagulants
Q38101915	Multiple comparisons in complex clinical trial designs
Q37115545	My Patient Taking A Novel Oral Anticoagulant Needs Surgery, Device Implantation, Or Ablation
Q89338753	NOAC in "real world" patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study
Q38723893	NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis
Q41524034	NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
Q36315659	National Trends in Ambulatory Oral Anticoagulant Use.
Q36376021	National trends in oral anticoagulant use in the United States, 2007 to 2011
Q33553982	National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries
Q47135358	Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era.
Q33928117	Navigating the gray zones of stroke management for a graying population
Q28546594	Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis
Q37617079	Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care.
Q44979972	Neurosurgical implications of dabigatran-associated intracerebral hemorrhage
Q42907047	New Approaches to Stroke Prevention in Atrial Fibrillation
Q54975871	New Direct Oral Anticoagulants (DOAC) and Their Use Today.
Q28081366	New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)
Q38970532	New Oral Anticoagulants and Their Reversal Agents
Q28066141	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation
Q38560059	New Oral Anticoagulants: How Do We Use Them Wisely?
Q37495909	New Stroke Prophylaxis Options in Atrial Fibrillation Patients
Q87017737	New Target-Specific Oral Anticoagulants and Intracranial Bleeding: Management and Outcome in a Single-Center Case Series
Q38238950	New advances in the treatment of atrial fibrillation: focus on stroke prevention
Q42380488	New agents to prevent strokes in nonvalvular atrial fibrillation.
Q42907043	New and Emerging Anticoagulant Therapies for Venous Thromboembolism
Q43089759	New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation
Q33397359	New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome
Q44231514	New and old anti-thrombotic treatments for patients with atrial fibrillation
Q37996449	New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation
Q37899258	New anticoagulants - promising and failed developments.
Q38176801	New anticoagulants and antiplatelet agents: a primer for the clinical gastroenterologist
Q51778867	New anticoagulants and the future of cardiology.
Q37920447	New anticoagulants for atrial fibrillation: the beginning of a a new era in stroke prevention.
Q37888758	New anticoagulants for prevention of stroke in patients with atrial fibrillation
Q38040459	New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence
Q37924879	New anticoagulants for the prevention of stroke in atrial fibrillation
Q38831847	New anticoagulants for the treatment of venous thromboembolism
Q47791209	New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds
Q38085786	New anticoagulants in atrial fibrillation management.
Q42385248	New anticoagulants in atrial fibrillation: an update for clinicians
Q84979232	New anticoagulants in internal medicine: An update
Q38005012	New anticoagulants in ischemic heart disease
Q41289984	New anticoagulants in the treatment of atrial fibrillation in 2011.
Q38043378	New anticoagulants: A concise review
Q37900670	New anticoagulants: how to deal with treatment failure and bleeding complications
Q37853073	New anticoagulants: pharmacology and clinical studies
Q37768334	New antithrombotic agents--insights from clinical trials
Q43183600	New antithrombotic drugs
Q84799493	New antithrombotic drugs and European approval processes
Q83344166	New antithrombotic drugs for atrial fibrillation: caution is needed
Q43077501	New antithrombotic drugs: a revolution in stroke management.
Q38065063	New avenues for anticoagulation in atrial fibrillation
Q36087596	New chronic disease medication prescribing by nurse practitioners, physician assistants, and primary care physicians: a cohort study
Q38757796	New developments in clinical ischemic stroke prevention and treatment and their imaging implications
Q34753085	New drugs approved in 2010
Q38061141	New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran
Q37977275	New frontiers for stroke prevention in atrial fibrillation.
Q39027027	New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention
Q47099414	New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery
Q26786574	New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism
Q34906214	New options in anticoagulation for the prevention of venous thromboembolism and stroke.
Q33888320	New options with dabigatran etexilate in anticoagulant therapy
Q90561976	New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients
Q38336863	New oral anti-coagulants: Implications for neurosurgery
Q64320006	New oral anti-coagulation drugs and prostate biopsy: a call for guidelines
Q37140964	New oral anticoagulant agents after ACS.
Q38513891	New oral anticoagulant and antiplatelet agents for neurosurgeons.
Q34629479	New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future
Q54257622	New oral anticoagulant drugs: real-world data.
Q38652425	New oral anticoagulant prescription rate and risk of bleeding in an Italian region.
Q37843749	New oral anticoagulants
Q86039426	New oral anticoagulants and pituitary apoplexy
Q37519054	New oral anticoagulants and the cancer patient.
Q21132464	New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons
Q36247011	New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted
Q26849452	New oral anticoagulants for atrial fibrillation
Q37641289	New oral anticoagulants for atrial fibrillation: are they worth the risk?
Q38286236	New oral anticoagulants for nonvalvular atrial fibrillation in the elderly: Limited applicability in primary care
Q38068593	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation
Q37340021	New oral anticoagulants for stroke prevention in atrial fibrillation: more choices bring more challenges
Q58420677	New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials
Q34331671	New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
Q38068113	New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures
Q35160888	New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials
Q43455101	New oral anticoagulants in heart failure
Q38105041	New oral anticoagulants in non-valvular atrial fibrillation.
Q88225131	New oral anticoagulants in patients with atrial fibrillation
Q88225137	New oral anticoagulants in patients with atrial fibrillation - Authors'reply
Q38180988	New oral anticoagulants in practice: pharmacological and practical considerations
Q33765879	New oral anticoagulants may be particularly useful for asian stroke patients
Q30913842	New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials.
Q39717286	New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation
Q33791997	New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
Q38930008	New oral anticoagulants: a practical guide for physicians
Q38221642	New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Q38038905	New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function
Q37992582	New oral anticoagulants: a view from the laboratory
Q54610809	New oral anticoagulants: an emergency department overview.
Q39844305	New oral anticoagulants: appropriateness of prescribing in real-world setting
Q37593158	New oral anticoagulants: are coagulation units still required?
Q42920623	New oral anticoagulants: better than vitamin K antagonists?
Q38203298	New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications
Q38071973	New oral anticoagulants: comparative pharmacology with vitamin K antagonists
Q42091475	New oral anticoagulants: discussion on monitoring and adherence should start now!
Q84819080	New oral anticoagulants: just a new therapeutic option or a real breakthrough?
Q28080616	New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
Q35739671	New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders
Q38071934	New oral therapies for the prevention and treatment of venous thromboembolism
Q38166368	New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants
Q38543287	New strategies for effective treatment of vitamin K antagonist-associated bleeding
Q55442446	Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis.
Q38878032	Newer Oral Anticoagulants: Stroke Prevention and Pitfalls
Q37148738	Newer anticoagulants for non-valvular atrial fibrillation
Q38220693	Newer clinically available antithrombotics and their antidotes
Q38019591	Newer oral anticoagulant agents: a new era in medicine
Q51722454	Newer oral anticoagulants: a promising future.
Q38035267	Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient
Q26865345	Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'
Q27334041	No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke
Q42390513	Non vitamin K anticoagulation drugs will win the race
Q35776351	Non-Traumatic Spontaneous Spinal Subdural Hematoma in a Patient with Non-Valvular Atrial Fibrillation During Treatment with Rivaroxaban
Q28081918	Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review
Q92680874	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies
Q64096249	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
Q91923022	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis
Q35974298	Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis
Q90568724	Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation
Q90567520	Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
Q39452481	Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.
Q26750767	Non-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues
Q88528330	Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis
Q38008055	Non-inferiority study design: lessons to be learned from cardiovascular trials
Q40503229	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
Q35990778	Non-pharmacological therapy for atrial fibrillation: managing the left atrial appendage
Q37931364	Non-surgical left atrial appendage closure for stroke prevention in atrial fibrillation
Q89177871	Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role?
Q58586064	Non-vitamin K Antagonist Oral Anticoagulants and Cognitive Impairment in Atrial Fibrillation: Insights From the Meta-Analysis of Over 90,000 Patients of Randomized Controlled Trials and Real-World Studies
Q53281556	Non-vitamin K Antagonist Oral Anticoagulants vs. Warfarin at Risk of Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Q38685824	Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Q34672746	Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials
Q38236215	Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations
Q28067420	Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome
Q28087146	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation
Q35650348	Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
Q38287155	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?
Q38175211	Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions
Q47717078	Non-vitamin K antagonist oral anticoagulants versus warfarin for the prevention of spontaneous echo-contrast and thrombus in patients with atrial fibrillation or flutter undergoing cardioversion: A trans-esophageal echocardiography study
Q38662571	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation
Q36100271	Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation
Q30853679	Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Q37166491	Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark
Q64251112	Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study - data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA)
Q33897825	Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Q39643837	Non-vitamin K oral anticoagulants in patients with atrial fibrillation after cardiac surgery: the results of the European Heart Rhythm Association Survey
Q38964210	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease
Q28071657	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
Q38708508	Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
Q94230261	Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis
Q35883245	Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack
Q92358641	Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
Q38838530	Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.
Q39396573	Novel Oral Anticoagulants in Patients Undergoing Cranial Surgery
Q38793747	Novel anticoagulants - an update on the latest developments and management for clinicians treating patients on these drugs
Q38390684	Novel anticoagulants and antiplatelet agents; a guide for the urologist
Q37946861	Novel anticoagulants for atrial fibrillation: a critical appraisal
Q34692850	Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.
Q38155933	Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly
Q38212962	Novel anticoagulants for stroke prevention in patients with atrial fibrillation
Q36443814	Novel anticoagulants in atrial fibrillation stroke prevention
Q87680210	Novel anticoagulants should NOT be recommended for high-risk activity
Q64092978	Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation - a meta-analysis of more than 17000 patients
Q38589533	Novel anticoagulants: general overview and practical considerations for dental practitioners
Q26784125	Novel antidotes for target specific oral anticoagulants
Q57179203	Novel aspects of antiplatelet therapy in cardiovascular disease
Q37998113	Novel drugs for oral anticoagulation pharmacotherapy
Q48146670	Novel oral anticoagulant drugs and severe oesophagitis dissecans.
Q38910667	Novel oral anticoagulant management issues for the stroke clinician
Q97539858	Novel oral anticoagulant vs. warfarin in elderly atrial fibrillation patients with normal, mid-range, and reduced left ventricular ejection fraction
Q48165365	Novel oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and diabetes-Good or excellent?
Q37995563	Novel oral anticoagulants after acute coronary syndromes
Q38116784	Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure
Q26771544	Novel oral anticoagulants and the 73rd anniversary of historical warfarin
Q37961824	Novel oral anticoagulants and their role in clinical practice
Q56971160	Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?
Q38114002	Novel oral anticoagulants for atrial fibrillation
Q36723401	Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient
Q38017613	Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban
Q38087191	Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation
Q38079915	Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Q38162796	Novel oral anticoagulants for stroke prevention in the geriatric population.
Q38158212	Novel oral anticoagulants for the prevention and treatment of thromboembolism
Q37197199	Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis
Q44691762	Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation
Q38075841	Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin
Q38137852	Novel oral anticoagulants in cardiovascular disease
Q34666804	Novel oral anticoagulants in non-valvular atrial fibrillation
Q47365787	Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation
Q49980176	Novel oral anticoagulants in the preoperative period: a meta-analysis.
Q37697501	Novel oral anticoagulants to prevent stroke in atrial fibrillation
Q37595758	Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.
Q37810102	Novel oral anticoagulants. Part II: direct thrombin inhibitors
Q38154728	Novel oral anticoagulants: a focused review for stroke physicians
Q38128173	Novel oral anticoagulants: a review of new agents.
Q38087188	Novel oral anticoagulants: a review of the literature and considerations in special clinical situations
Q38101845	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations
Q34627780	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism
Q38127582	Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal
Q37990317	Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome
Q39178470	Novel stroke risk reduction in atrial fibrillation: left atrial appendage occlusion with a focus on the Watchman closure device
Q37548399	Novel treatments for cardiovascular disease prevention.
Q35108548	Nurses' self-reported time estimation of anticoagulation therapy: a survey of warfarin management in long-term care
Q39497957	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study
Q50951554	Odds ratio vs risk ratio in randomized controlled trials.
Q37831332	Old and new anticoagulant drugs: a minireview
Q53559263	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation.
Q42286343	Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation
Q39639280	Ophthalmic Complications Associated with Direct Oral Anticoagulant Medications
Q26796407	Ophthalmic regional blocks: management, challenges, and solutions
Q40033352	Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation.
Q96303820	Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
Q45326620	Optimal dabigatran dosage in patients with moderate renal impairment
Q50003159	Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
Q38078754	Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms
Q54968663	Optimal long-term antithrombotic management of atrial fibrillation: life cycle management.
Q46827098	Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter
Q36051855	Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate?
Q37468892	Optimization Of Stroke Prophylaxis Strategies In Nonvalvular AF -Drugs, Devices Or Both?
Q36802853	Optimization of Stroke Prophylaxis Strategies in Nonvalvular AF - Drugs, Devices or Both?
Q41254233	Optimizing the dose of dabigatran etexilate
Q37766393	Optimizing the management of atrial fibrillation: focus on current guidelines and the impact of new agents on future recommendations
Q38124014	Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly
Q39066781	Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention
Q35966802	Oral Anticoagulant Prescription in Patients With Atrial Fibrillation and a Low Risk of Thromboembolism: Insights From the NCDR PINNACLE Registry
Q31170904	Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort.
Q94539429	Oral Anticoagulants and Precision Medicine: Something Old, Something New
Q91867503	Oral Anticoagulants in Japanese Patients with Atrial Fibrillation and Active Cancer
Q50142620	Oral Anticoagulation in Atrial Fibrillation: Development and Evaluation of a Mobile Health Application to Support Shared Decision-Making.
Q58578133	Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation
Q64962466	Oral Anticoagulation.
Q50454802	Oral anticoagulant agent-associated bleeding events reporting system (ORANGE) study.
Q42706796	Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Q34342679	Oral anticoagulant therapies: balancing the risks
Q35105020	Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital
Q34252907	Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Q58781692	Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
Q37900185	Oral anticoagulant-associated intracerebral hemorrhage
Q38239244	Oral anticoagulants and status of antidotes for the reversal of bleeding risk.
Q38194842	Oral anticoagulants for Asian patients with atrial fibrillation
Q47142865	Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Q38380476	Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
Q38076076	Oral anticoagulants in older adults with atrial fibrillation
Q38124826	Oral anticoagulants to reduce the risk of stroke in atrial fibrillation: how should a clinician choose?
Q44115938	Oral anticoagulants--a frequent challenge for the emergency management of acute ischemic stroke
Q34641456	Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed
Q38068455	Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts
Q58605572	Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients
Q38113554	Oral anticoagulation therapy for elderly patients with atrial fibrillation: utility of bleeding risk covariates to better understand and moderate risks
Q64100006	Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016
Q36567348	Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies
Q36729949	Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects
Q37988788	Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation
Q26780154	Oral direct thrombin inhibition: a double-edged sword?
Q40259127	Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients
Q24186935	Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis
Q24200867	Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis
Q24187205	Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Q24200864	Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism
Q37978093	Oral factor Xa and direct thrombin inhibitors: a clinical perspective
Q49834369	Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series.
Q90480719	Out-of-range INR results lead to increased health-care utilization in four large anticoagulation clinics
Q37496191	Outcome of Patients Discharged after their First Detected Episode of Atrial Fibrillation
Q45119524	Outcome of coumarin-therapy in an outpatient setting over a 10-year period: coumarin-therapy in clinical practice
Q35681742	Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis
Q30458291	Outcomes Associated With Prothrombin Complex Concentrate for International Normalized Ratio Reversal in Patients on Oral Anticoagulants With Acute Bleeding
Q56355648	Outcomes Associated with Apixaban Use in End-Stage Kidney Disease Patients with Atrial Fibrillation in the United States
Q34091490	Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry
Q39953513	Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation
Q45326127	Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation
Q33828157	Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims
Q43712493	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial
Q34388837	Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention o
Q38972270	Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants
Q38826151	Overview of direct oral anticoagulant therapy reversal
Q38014344	PAR-1 antagonists: current state of evidence
Q36638187	PAR-1 contributes to the innate immune response during viral infection.
Q35247502	PURLs: Time to try this warfarin alternative?
Q38871417	Paroxysmal Atrial Fibrillation: Novel Strategies for Monitoring and Implications for Treatment in Stroke
Q38097511	Paroxysmal atrial fibrillation after ischemic stroke: how should we hunt for it?
Q35784686	Paroxysmal atrial fibrillation and the hazards of under-treatment
Q59191961	Patent foramen ovale
Q40175981	Patient Characteristics and Antithrombotic Prescribing Patterns in Patients With Atrial Fibrillation in Tasmania
Q38663218	Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran
Q45299197	Patient Failure to Seek Care for Non-ST-Elevated Myocardial Infarction Because of Symptoms Being Attributed to Dyspepsia From Dabigatran
Q92592575	Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
Q37596798	Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review
Q91643495	Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study)
Q37268085	Patient perspectives of dabigatran: analysis of online discussion forums.
Q37208427	Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study.
Q39717056	Patient satisfaction with extended-interval warfarin monitoring
Q44714275	Patient selection for the implantation of a left atrial appendage occluder in primary and secondary prevention of cardioembolic stroke in atrial fibrillation
Q36217719	Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study
Q87206073	Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey
Q92702829	Patients with Heart Failure and Preserved Ejection Fraction Are at Risk of Gastrointestinal Bleeding
Q48255595	Patients with atrial fibrillation and diabetes: does apixaban remain the drug of choice?
Q38078302	Patients with stable, therapeutic INR values should remain on warfarin
Q60716839	Patients' Priorities for Oral Anticoagulation Therapy in Non-valvular Atrial Fibrillation: a Multi-criteria Decision Analysis
Q34514298	Patients' perspectives regarding long-term warfarin therapy and the potential transition to new oral anticoagulant therapy
Q48563936	Patients' preferences for new versus old anticoagulants: a mixed-method vignette-based study
Q37586922	Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER
Q48233579	Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study.
Q57823505	Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study
Q45140840	Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of Dementia
Q88195597	Percutaneous Coronary Intervention in Patients Who Have an Indication for Oral Anticoagulation - an Evidence-based Approach to Antithrombotic Therapy
Q47149613	Percutaneous Left Atrial Appendage Closure: is there a Role in Valvular Atrial Fibrillation
Q26797439	Percutaneous Left Atrial Appendage Ligation for Stroke Prevention in Atrial Fibrillation
Q57494699	Percutaneous Left Atrial Appendage Occlusion for the Prevention of Stroke in Patients with Atrial Fibrillation: Review and Critical Appraisal
Q38244025	Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma
Q38365382	Percutaneous left atrial appendage closure: Technical aspects and prevention of periprocedural complications with the watchman device
Q42384687	Percutaneous left atrial appendage closure: here to stay
Q34333253	Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update
Q26825351	Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies
Q47330371	Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review
Q49908617	Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review.
Q39368747	Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicenter registry
Q31122441	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies
Q46233108	Percutaneous management of late leak after lariat transcatheter ligation of the left atrial appendage in patients with atrial fibrillation at high risk for stroke
Q44695044	Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels
Q35062723	Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial
Q45841050	Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry
Q37062044	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
Q96111422	Perioperative antithrombotic management of patients who receive direct oral anticoagulants during gastroenterological surgery
Q92983756	Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis
Q90480584	Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis
Q35758792	Perioperative management of antithrombotic and antiplatelet therapy
Q40069714	Perioperative management of antithrombotic therapy in patients receiving cardiovascular implantable electronic devices: a network meta-analysis
Q40169685	Perioperative management of new oral anticoagulants in patients undergoing elective surgery at a tertiary hospital.
Q38254247	Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants
Q33692054	Perioperative management of patients on direct oral anticoagulants.
Q39201951	Perioperative management of patients on new oral anticoagulants
Q38037974	Perioperative stroke risk in nonvascular surgery
Q26781790	Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: an analysis of the implications for perioperative management
Q93143130	Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study
Q57907842	Periprocedural Anticoagulant Management
Q47713122	Periprocedural Anticoagulation Management for Atrial Fibrillation Ablation: Current Knowledge and Future Directions
Q57778765	Periprocedural Dabigatran in Atrial Fibrillation Ablation: A New Kid on the Block
Q64978750	Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures.
Q38398014	Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation
Q28071393	Periprocedural Management of Non-Vitamin K Oral Anticoagulants in Chronic Kidney Disease: A Review of Existing Heterogeneity and Contemporary Evidence
Q47783321	Periprocedural coagulability in patients undergoing ablation of atrial fibrillation: lessons from a periablation anticoagulation strategy of a brief withdrawal of warfarin without heparin bridging
Q42549764	Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials
Q36352841	Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study
Q92983760	Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
Q96682530	Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up
Q40417806	Persistent ductus arteriosus in a 72-year-old woman with paroxysmal atrial fibrillation and depression syndrome: a therapeutic and diagnostic problem
Q42867752	Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation
Q26822796	Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics
Q33776783	Personalized approach to primary and secondary prevention of ischemic stroke
Q30663685	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference
Q38129965	Personalizing oral anticoagulant treatment in patients with atrial fibrillation
Q55309883	Pharmacist Interventions Regarding the Appropriateness of Apixaban, Rivaroxaban, Dabigatran, and Warfarin in a University-Affiliated Outpatient Clinic.
Q45041990	Pharmacist prescribing within an integrated health system in Washington
Q47135589	Pharmacists' confidence when providing pharmaceutical care on anticoagulants, a multinational survey.
Q38386660	Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation
Q37847150	Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery
Q55717925	Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.
Q38148597	Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.
Q43115875	Pharmacogenetics of coumarinic oral anticoagulants
Q33819050	Pharmacogenetics of warfarin: challenges and opportunities
Q57179825	Pharmacogenomics Aspect of Warfarin Therapy
Q37967607	Pharmacogenomics in neurology: current state and future steps
Q38024094	Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation
Q38113231	Pharmacokinetic considerations for antithrombotic therapies in stroke
Q33403263	Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome
Q46718279	Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin
Q37997507	Pharmacologic and nonpharmacologic therapies for stroke prevention in nonvalvular atrial fibrillation
Q38163036	Pharmacologic and nonpharmacologic thromboprophylactic strategies in atrial fibrillation
Q53150344	Pharmacologic strategies for the prevention of stroke in patients with atrial fibrillation.
Q37495788	Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents
Q45974877	Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation.
Q35685099	Pharmacological basis and clinical evidence of dabigatran therapy
Q33902193	Pharmacological management of atrial fibrillation: one, none, one hundred thousand.
Q90480565	Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature
Q60017830	Pharmacologie des anti-Xa et mécanismes d’action
Q38246726	Pharmacology and mechanisms of action of new oral anticoagulants.
Q38380461	Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments.
Q38104314	Pharmacology of the new target-specific oral anticoagulants
Q29584461	Pharmacometric characterization of dabigatran hemodialysis
Q58126977	Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF
Q38029077	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results
Q37785831	Phosphorylation mechanisms in intensive care medicine
Q48855024	Physician Preferences for Botulinum Toxin Injections in Anticoagulated Patients with Spasticity.
Q34551073	Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation
Q37585421	Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate
Q53100207	Pituitary apoplexy and rivaroxaban.
Q42061728	Planning and monitoring of patients for electrical cardioversion for atrial fibrillation
Q90745378	Plasma contact factors as therapeutic targets
Q50548817	Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus.
Q36988667	Plasminogen activators and ischemic stroke: conditions for acute delivery
Q28512072	Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis
Q58792339	Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis
Q36801083	Poor adherence to anticoagulation guidelines in patients with non-valvular atrial fibrillation treated in a tertiary cardiology unit
Q45857724	Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Q50506593	Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal.
Q37552525	Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes
Q45337754	Population-based study of acute- and long-term care costs after stroke in patients with AF.
Q92442059	Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure
Q38433830	Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation
Q42409132	Post-Procedural Dabigatran Versus Interrupted Warfarin Therapy Following Catheter Ablation for Atrial Fibrillation
Q36773627	Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
Q37040299	Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction: Insights From the HMO Research Network-Stent Registry
Q64115101	Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results
Q96303812	Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses
Q39465444	Potential Effect of Substituting Estimated Glomerular Filtration Rate for Estimated Creatinine Clearance for Dosing of Direct Oral Anticoagulants
Q38214960	Potential antidotes for reversal of old and new oral anticoagulants
Q37108889	Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care
Q36155695	Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke
Q36839479	Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.
Q38130753	Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran
Q38210994	Potential use of NOACs in developing countries: pros and cons.
Q38779146	Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation
Q87357276	Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation
Q41061213	Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation
Q37382897	Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation
Q26785480	Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care
Q37889781	Practical aspects of the oral new anticoagulants
Q38164313	Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation
Q38151988	Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation
Q37641965	Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
Q47155567	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants
Q91585084	Practical guide to choosing dabigatran 150 mg twice daily or apixaban 5 mg twice daily for patients with atrial fibrillation
Q39881610	Practical introduction of novel oral anticoagulants through an anticoagulation nurse. The Leeuwarden model
Q38365022	Practical issues in the management of novel oral anticoagulants-cardioversion and ablation
Q38093434	Practical issues, limitations, and periprocedural management of the NOAC's
Q41890211	Practical management of patients on apixaban: a consensus guide
Q55222788	Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa.
Q38096085	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
Q90151653	Practice Variations in the Use of Novel Oral Anticoagulants for Nonvalvular Atrial Fibrillation-Related Stroke among Stroke Neurologists in Saudi Arabia
Q64981317	Pradaxa, bleeding and tort litigation solicitation.
Q40959389	Pradaxa-induced esophageal ulcer
Q48195237	Pragmatic approach to manage new oral anticoagulants in patients undergoing dental extractions: a prospective case-control study.
Q38992769	Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program
Q36648875	Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target
Q38426743	Preclinical safety evaluation of low molecular weight heparin-deoxycholate conjugates as an oral anticoagulant
Q96431920	Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling
Q89694368	Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States
Q58099349	Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review
Q91996353	Predicting outcomes in patients with cancer and atrial fibrillation
Q35991881	Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record
Q47136092	Prediction Score for Anticoagulation Control Quality Among Older Adults
Q33637902	Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing
Q24658646	Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study
Q37885792	Prediction of stroke risk in atrial fibrillation, prevention of stroke in atrial fibrillation, and the impact of long-term monitoring for detecting atrial fibrillation
Q37989489	Prediction of warfarin dose: why, when and how?
Q55408544	Predictors of Cardioembolic Stroke in Japanese Patients with Atrial Fibrillation in the Fushimi AF Registry.
Q57470585	Predictors of Major Bleeding Among Working-Age Adults with Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug Interactions and Switching from Warfarin to Non-vitamin K Oral Anticoagulants
Q45394833	Predictors of anticoagulant treatment in patients with nonvalvular atrial fibrillation: results from atrial fibrillation in Turkey: epidemiologic registry
Q36571742	Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.
Q38202066	Predictors of long-term maintenance of normal sinus rhythm after successful electrical cardioversion
Q57817732	Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: a retrospective observational study in Southern Italy
Q99608096	Predictors of oral anticoagulant-associated adverse events in seniors transitioning from hospital to home: a retrospective cohort study protocol
Q34150474	Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis
Q93092382	Preemptive Dose Adjustment Effect on the Quality of Anticoagulation Management in Warfarin Patients With Drug Interactions: A Retrospective Cohort Study
Q61439743	Preferences for Oral Anticoagulants in Atrial Fibrillation: a Best–Best Discrete Choice Experiment
Q50996554	Preferences for anticoagulation therapy in atrial fibrillation: the patients' view.
Q35109765	Pregnancy and stroke risk in women
Q90269760	Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis
Q37376804	Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.
Q47834184	Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments
Q91824221	Prescribing of oral anticoagulants in the emergency department and subsequent long-term use by older adults with atrial fibrillation
Q37701833	Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis
Q36956176	Prescribing patterns of target-specific oral anticoagulants: an academic hospital perspective
Q39193511	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant
Q47781420	Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database
Q38506687	Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution
Q34389483	Present concepts in management of atrial fibrillation: From drug therapy to ablation
Q37468856	Preserving Cognitive Function in Patients with Atrial Fibrillation
Q37945123	Prevalence and predictors of warfarin use in patients with atrial fibrillation at low or intermediate risk and relation to thromboembolic events.
Q40065521	Prevalence of Intracranial Hemorrhage after Blunt Head Trauma in Patients on Pre-injury Dabigatran
Q43731593	Prevalence of atrial fibrillation in intracerebral hemorrhage
Q40896979	Prevalence of auricular thrombosis before atrial flutter cardioversion: a 17-year transoesophageal echocardiographic study
Q34317008	Prevalence of oral anticoagulation in atrial fibrillation
Q43960867	Prevalence of renal dysfunction in ischaemic stroke and transient ischaemic attack patients with or without atrial fibrillation
Q49607144	Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
Q37496186	Preventative Measures of Stroke in Patients With Atrial Fibrillation
Q26801820	Preventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgery
Q35938914	Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants
Q38012077	Preventing venous thromboembolic events after total hip arthroplasty: new developments in clinical practice
Q37918319	Prevention and management of TURP-related hemorrhage
Q38369639	Prevention and management of stroke in women.
Q37495942	Prevention of Stroke by Antithrombotic Therapy in Patients with Atrial Fibrillation
Q53762661	Prevention of Stroke in Patients With Atrial Fibrillation.
Q26866343	Prevention of cardioembolic stroke
Q35648111	Prevention of cardioembolic stroke
Q37799361	Prevention of cardioembolic stroke in patients with atrial fibrillation
Q57313061	Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
Q44497235	Prevention of stroke in atrial fibrillation
Q50590025	Prevention of stroke in atrial fibrillation: cautious optimism.
Q38011969	Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options
Q37738308	Prevention of stroke in patients with high-risk atrial fibrillation
Q43245199	Prevention of stroke: what is evidence based?
Q34072190	Prevention strategies for cardioembolic stroke: present and future perspectives
Q36374086	Primary Care Atrial Fibrillation Service: outcomes from consultant-led anticoagulation assessment clinics in the primary care setting in the UK
Q38935753	Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice
Q36372800	Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis
Q36402738	Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial
Q49602689	Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants.
Q58127431	Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation
Q36295826	Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting
Q38651209	Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial
Q33159661	Progress in cardiac electrophysiology and arrhythmias
Q43133217	Progress in clinical cardiology: surface electrocardiography, cardiovascular disease in women, and novel therapies
Q39519636	Promise and challenges of anticoagulation with dabigatran
Q37959870	Promise of factor Xa inhibition in atrial fibrillation
Q40449888	Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin.
Q38130269	Prophylaxis and treatment of venous thromboembolism in the critically ill.
Q51335375	Proportion of patients with implanted permanent pacemakers with atrial fibrillation receiving appropriate medical prophylaxis in North Wales.
Q37258480	Prospective observational studies of the management and outcomes in patients with atrial fibrillation: A systematic review
Q39037268	Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation
Q38101903	Protecting the brain and the heart: antithrombotic treatment in nonvalvular atrial fibrillation
Q40765852	Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
Q45849904	Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.
Q27006890	Protocol in managing oral surgical patients taking dabigatran
Q57457919	Provider Specialty, Anticoagulation, and Stroke Risk in Patients With Atrial Fibrillation and Cancer
Q43114521	Pulmonary circulation: contributions of the year 2009
Q48151090	Pulmonary embolism in a morbidly obese patient receiving dabigatran.
Q48533036	Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana.
Q38666184	Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review
Q37278238	Quality of anticoagulation control among patients with atrial fibrillation: An experience of a tertiary care center in Saudi Arabia
Q40083909	Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users
Q42923266	Quality of anticoagulation control in atrial fibrillation
Q52611098	Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.
Q35099559	Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL
Q92689234	Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort
Q47823178	Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry.
Q42740448	RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves - The search continues
Q87864462	Race and stroke in an atrial fibrillation inception cohort: Findings from the Penn Atrial Fibrillation Free study
Q44392727	Race/Ethnicity in Atrial Fibrillation Stroke: Epidemiology and Pharmacotherapy
Q89807751	Racial/Ethnic Disparities in Atrial Fibrillation Treatment and Outcomes among Dialysis Patients in the United States
Q46241001	Rash associated with dabigatran etexilate
Q90136324	Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study
Q36586263	Rates of hemorrhage during warfarin therapy for atrial fibrillation
Q27692632	Rationale and current perspective for early rhythm control therapy in atrial fibrillation.
Q33552973	Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa)
Q51039938	Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation.
Q38598162	Rationale and design of a global registry to evaluate real-world clinical outcomes in patients with atrial fibrillation and high risk of stroke treated with left atrial appendage occlusion using the AMPLATZER amulet device-Perspective of available/o
Q90480448	Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism
Q36042046	Rationale and design of the Chinese Atrial Fibrillation Registry Study
Q37523123	Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III.
Q40378922	Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation
Q40799525	Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation
Q93152657	Rationale and design of the Registry of Acute Stroke Under Novel Oral Anticoagulants-prime (RASUNOA-prime)
Q92776922	Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study
Q38939453	Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
Q28067358	Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed
Q30660067	Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.
Q37664588	ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study).
Q31098679	Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
Q61808973	Real World Comparison of Rivaroxaban and Warfarin in Korean Patients with Atrial Fibrillation: Propensity Matching Cohort Analysis
Q45005687	Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use
Q47210396	Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation
Q38653946	Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation
Q49477401	Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation.
Q37990615	Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry
Q38694936	Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry
Q47114806	Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients
Q36784701	Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants?
Q46050727	Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan
Q37201505	Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation
Q48362648	Real-world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies.
Q99565674	Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
Q54975650	Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset.
Q48106164	Real-world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center
Q38378124	Real-world stroke prevention strategies in nonvalvular atrial fibrillation in patients with renal impairment
Q96584449	Real-world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A meta-analysis
Q41671084	Real-world variability in dabigatran levels in patients with atrial fibrillation
Q38665579	Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease
Q36461724	Recent Atrial Fibrillation Guidelines - Looking at Both Sides of the Atlantic
Q44960297	Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation
Q37802084	Recent advances in oral anticoagulation for atrial fibrillation
Q28256340	Recent advances in the development of specific antidotes for target-specific oral anticoagulants
Q47102311	Recent advances in the management of transient ischemic attacks
Q33851708	Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants
Q37577697	Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention
Q38009238	Recent clinical trials in atrial fibrillation in hypertensive patients.
Q55072550	Recent progress and market analysis of anticoagulant drugs.
Q37903926	Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.
Q36916381	Recent trends in cost-related medication nonadherence among stroke survivors in the United States
Q37443166	Recently published papers: Novel therapies in chronic obstructive pulmonary disease, cardiac chemicals and intensive care outcomes
Q34589983	Recommendations for stroke in 2010: a challenging agenda
Q42928680	Recommendations for stroke: 2010.
Q38106596	Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban
Q36515685	Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.
Q38169965	Recommendations for the use of new oral anticoagulants (NOACs) after TIA or stroke caused by atrial fibrillation (AF), after a consensus conference among Italian neurologists (the Venice group).
Q42119323	Recurrent, delayed hemorrhage associated with edoxaban after deep brain stimulation lead placement
Q45307497	Reduced risk of death with warfarin - results of an observational nationwide study of 20 442 patients with atrial fibrillation and ischaemic stroke
Q28077755	Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?
Q48854658	Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Q37826515	Reducing post-stroke disability in diabetic patients
Q58375663	Reducing the risk of recurrent stroke in patients with AF
Q37613761	Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians
Q99596913	Reduction in Stroke after TIA in a Province-Wide Cohort Between 2003-2015
Q50048396	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.
Q37710165	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions
Q38921165	Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when?
Q42868367	Relation between frequency of activated partial prothrombin time measurements and clinical outcomes in patients after initiation of dabigatran: A two-center cooperative study
Q92633295	Relationship between the Renal Function and Adverse Clinical Events in Patients with Atrial Fibrillation: A Japanese Multicenter Registry Substudy
Q51733104	Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation.
Q35321909	Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis
Q38330349	Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban
Q37843855	Remote patient management using implantable devices
Q38270489	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis
Q89269052	Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant
Q37879330	Renal profiles of anticoagulants
Q38660256	Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding
Q41924009	Replacement of warfarin with a novel oral anticoagulant in endoscopic mucosal resection: a multicentre, open-label, randomised controlled trial.
Q48152726	Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study).
Q36496360	Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database
Q41844246	Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban.
Q37606144	Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: A case report and literature review
Q86071255	Restarting oral anticoagulants after intracerebral hemorrhage: pros
Q92462968	Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration
Q50333195	Reversal Agents in the Era of NOACs.
Q39642830	Reversal of Dabigatran with Idarucizumab
Q37998377	Reversal of antithrombotic agents
Q38831682	Reversal of dabigatran by idarucizumab: when and how?
Q88313532	Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients
Q48341889	Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
Q53123393	Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.
Q39170777	Reversal of direct oral anticoagulants.
Q38009420	Reversal of drug-induced anticoagulation: old solutions and new problems
Q26827835	Reversal of oral anticoagulation
Q65001893	Reversal of the Anticoagulation Effects of Dabigatran Etexilate by Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke.
Q52892786	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular
Q26764882	Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
Q30400249	Reversing the anticoagulation effects of dabigatran
Q35768553	Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents
Q38097727	Review of challenges in optimizing oral anticoagulation therapy for stroke prevention in atrial fibrillation
Q37845022	Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation
Q34680367	Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.
Q38264260	Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials
Q37073908	Review of the top 5 cardiology studies of 2011-12.
Q35900749	Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011.
Q57770800	Risicoreductie en Number Needed to Treat
Q36458898	Risk Stratification in Atrial Fibrillation Patients - A Review Focused on Mortality
Q33876319	Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis
Q55263049	Risk factors and prevention of dabigatran-related gastrointestinal bleeding in patients with atrial fibrillation.
Q36524433	Risk factors for intracerebral hemorrhage differ according to hemorrhage location
Q36774021	Risk factors for postoperative bleeding after gastric endoscopic submucosal dissection in patients under antithrombotics
Q26783473	Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis
Q37595293	Risk of Gastrointestinal Bleeding Among Dabigatran Users - A Self Controlled Case Series Analysis
Q38802384	Risk of Intracranial Hemorrhage in Ground-level Fall With Antiplatelet or Anticoagulant Agents
Q38661148	Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis
Q37468787	Risk of Ischemic Stroke and Stroke Prevention in Patients with Atrial Fibrillation and Renal Dysfunction
Q36113146	Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation
Q40740723	Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity-Matched Analysis
Q30000079	Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry
Q38929892	Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study
Q46183835	Risk of bleeding with dabigatran in atrial fibrillation
Q38183208	Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis
Q41725412	Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study
Q35550900	Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study
Q39280394	Risk of gastrointestinal bleeding during anticoagulant treatment
Q58715507	Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study
Q48565298	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
Q33821854	Risk of ischemic stroke after atrial fibrillation diagnosis: A national sample cohort
Q40749422	Risk of long-term anticoagulation under sustained severe arterial hypertension: A translational study comparing warfarin and the new oral anticoagulant apixaban
Q40333529	Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study
Q36508477	Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study
Q38712351	Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies
Q38888217	Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants
Q47325163	Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study
Q35640960	Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis
Q33768602	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials
Q46109094	Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population
Q34737465	Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry
Q33927278	Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation?
Q36066774	Risk stratification of patients with atrial fibrillation: Biomarkers and other future perspectives.
Q38099570	Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly
Q34918312	Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap?
Q90008648	Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation
Q55518927	Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
Q37141430	Rivaroxaban - a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases
Q93024297	Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios
Q42188952	Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
Q83608797	Rivaroxaban and recurrent stroke prevention in AF
Q38221812	Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence
Q42415890	Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke
Q55361115	Rivaroxaban does not influence hemorrhagic transformation in a diabetes ischemic stroke and endovascular thrombectomy model.
Q40183661	Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer
Q38032618	Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome
Q38048832	Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial
Q90466695	Rivaroxaban for treatment of intraventricular thrombus in Chagas disease
Q36207101	Rivaroxaban in atrial fibrillation
Q57183343	Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
Q40499245	Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care
Q48592449	Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial
Q51058191	Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Q92492256	Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis
Q38108855	Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Q38081149	Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications
Q38107177	Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation
Q53170361	Role for the left atrial appendage occlusion device in managing thromboembolic risk in atrial fibrillation.
Q38790466	Role of Cardiac Imaging for Catheter-based Left Atrial Appendage Closure
Q57128725	Role of Thromboelastography and Rotational Thromboelastometry in the Management of Cardiovascular Diseases
Q40667772	Role of anticoagulation in neurological practice
Q37998952	Role of antithrombotic agents in heart failure.
Q37899153	Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation
Q40891852	Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding
Q38068295	Role of new drugs for management of atrial fibrillation
Q38244764	Role of novel anticoagulants for patients with mechanical heart valves
Q90029290	Role of the anticoagulant monitoring service in 2018: beyond warfarin
Q38100729	Role of the new target specific oral anticoagulants in the management of anticoagulation for cardioversion and atrial fibrillation ablation
Q49231482	Role of transesophageal echocardiography during left atrial appendage occlusion device closure in a patient with non-valvular atrial fibrillation and angiodysplasia of the colon.
Q90724393	Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases
Q45023487	SCAI/ACC/HRS institutional and operator requirements for left atrial appendage occlusion.
Q92992061	SSRI co-medication with NOAC or VKA does not increase hospitalisation for bleeding: A retrospective nationwide cohort study in Austria 2010-2015
Q33949571	Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making
Q44501563	Safe use of hemodialysis for dabigatran removal before cardiac surgery
Q92206565	Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation
Q51741687	Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near-Real-Time Monitoring Program in Italy.
Q64089085	Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study
Q93072018	Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial
Q90114403	Safety and Efficacy of Direct Oral Anticoagulants for Atrial Fibrillation in Patients with Renal Impairment
Q36363158	Safety and Efficacy of Left Atrial Appendage Closure with the Amplatzer Cardiac Plug in Very High Stroke and Bleeding Risk Patients with Non-Valvular Atrial Fibrillation
Q52603887	Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
Q64231843	Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
Q39612619	Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Q38687974	Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs
Q93271966	Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data
Q38030522	Safety and efficacy of apixaban in the treatment of atrial fibrillation
Q37552980	Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Q91640041	Safety and efficacy of direct oral anticoagulants compared to Vitamin K antagonists postpercutaneous coronary interventions in patients with atrial fibrillation: A systematic review and meta-analysis
Q38066348	Safety and efficacy of new anticoagulants in patients with heart failure
Q51025724	Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach.
Q34627624	Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update
Q33941583	Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation
Q58575559	Safety of Acupuncture in Patients Taking Newer Oral Anticoagulants: A Retrospective Chart Review Study
Q57979142	Safety of Edoxaban 30 mg in Elderly Patients with Severe Renal Impairment
Q38953655	Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice
Q37723884	Safety of The Direct Oral Anticoagulant Edoxaban for Atrial Fibrillation After Cardiac Surgery: Pilot Study
Q42013753	Safety of anticoagulation with uninterrupted warfarin vs. interrupted dabigatran in patients requiring an implantable cardiac device
Q92962972	Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia
Q59811871	Safety of laparoscopic surgery in digestive diseases with special reference to antithrombotic therapy: A systematic review of the literature
Q27016072	Safety of new oral anticoagulant drugs: a perspective
Q43582249	Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation
Q38095224	Safety of new oral anticoagulants with dual antiplatelet therapy in patients with acute coronary syndromes
Q38766678	Safety of non-vitamin K antagonist oral anticoagulants - coronary risks
Q55038863	Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
Q51233459	Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation.
Q92334049	Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial
Q34554492	Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry
Q39029615	Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions
Q90480345	Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
Q53462605	Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Q38086826	Screening, isolation, and decolonization strategies for vancomycin-resistant enterococci or extended spectrum Beta-lactamase-producing organisms: a systematic review of the clinical evidence and health services impact.
Q38542428	Secondary prevention of stroke
Q38248457	Secondary prevention of stroke in the elderly: focus on drug therapy
Q43833530	Secondary prophylaxis of stroke from a neurological perspective
Q38173148	Secondary stroke prevention
Q34306688	Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice
Q37778989	Secondary stroke prevention.
Q26795568	Secondary stroke prevention: challenges and solutions
Q38270417	Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation
Q35650380	Selecting antithrombotic therapy for patients with atrial fibrillation
Q45405204	Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and
Q43466559	Selection of Medications to Prevent Stroke Among Individuals With Atrial Fibrillation : Update on Prevention of Stroke in Patients with AF.
Q53076603	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation.
Q58563482	Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study
Q42688289	Setting priorities in the health care sector - the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark
Q40420009	Severe necrotic oesophageal and gastric ulceration associated with dabigatran.
Q34354859	Severe non-traumatic bleeding events detected by computed tomography: do anticoagulants and antiplatelet agents have a role?
Q40595266	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment
Q34557287	Sex differences in treatment quality of self-managed oral anticoagulant therapy: 6,900 patient-years of follow-up
Q34836591	Sex- and gender-specific research priorities for the emergency management of heart failure and acute arrhythmia: proceedings from the 2014 Academic Emergency Medicine Consensus Conference Cardiovascular Research Workgroup
Q40242892	Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation
Q41997375	Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial
Q47713452	Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation
Q50946976	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial.
Q45255246	Short-term vascular risk: time to take notice?
Q55398440	Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?
Q85370189	Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation?
Q36201247	Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?
Q55265837	Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010-2015.
Q46668382	Significance of the learning curve in left atrial appendage occlusion with two different devices.
Q39037046	Silent Atrial Fibrillation: A Critical Review
Q50588031	Silent cerebral events as a result of left atrial catheter ablation do not cause neuropsychological sequelae--a MRI-controlled multicenter study.
Q37681956	Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
Q50102254	Simulation for predicting effectiveness and safety of new cardiovascular drugs in routine care populations.
Q47193041	Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer
Q57044145	Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial
Q38894516	Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies
Q38184644	Small molecule inhibitors in the treatment of cerebral ischemia.
Q64099129	Sociodemographic factors and choice of oral anticoagulant in patients with non-valvular atrial fibrillation in Sweden: a population-based cross-sectional study using data from national registers
Q37496280	Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation
Q53282671	Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
Q28072542	Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation
Q89976638	Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency
Q42289621	Spinal subarachnoid and subdural hematoma presenting as a Brown-Séquard-like myelopathy following minor trauma in a patient on dabigatran etexilate
Q37640888	Spontaneous Intracerebral Hemorrhage: Management
Q37638144	Spontaneous Thyroid Hemorrhage on Chronic Anticoagulation Therapy
Q36097621	Spontaneous ascending aortic intramural haematoma in a patient on dabigatran
Q36703689	Spontaneous subdural hematoma and antiplatelet therapy: Does efficacy of Ticagrelor come with added risk?
Q36472544	Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia
Q61866276	Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation†
Q28066262	Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
Q37240690	Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Q38598302	Standard and reduced doses of dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
Q41735109	Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial
Q48163723	Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol
Q57179093	State of play and future direction with NOACs: An expert consensus
Q34656150	State-of-the-art management of acute bleeding peptic ulcer disease
Q92612170	Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019
Q38080912	Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review
Q38285105	Strategies for urgent reversal of target-specific oral anticoagulants
Q48774020	Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
Q39250007	Strength of evidence for labeled dosing recommendations in renal impairment
Q55176626	Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants.
Q37961826	Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies
Q26771564	Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Q35602462	Stroke Genetics Update: 2011
Q36458805	Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions
Q30389813	Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease
Q53803663	Stroke Prevention in Atrial Fibrillation.
Q36874702	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants
Q64966462	Stroke Prevention in Atrial Fibrillation: Focus on Asian Patients.
Q28359631	Stroke Prevention in Atrial Fibrillation: Focus on Latin America
Q35811581	Stroke Prevention in Atrial Fibrillation: Where are We Now?
Q52682096	Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices.
Q30238633	Stroke Risk Factors, Genetics, and Prevention
Q37115147	Stroke Risk Predictor Scoring Systems in Atrial Fibrillation
Q58129758	Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHADS-VASc Scores: Findings From the ORBIT-AF I and II Registries
Q61797700	Stroke aetiological classification reliability and effect on trial sample size: systematic review, meta-analysis and statistical modelling
Q90224924	Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice
Q34269633	Stroke and bleeding risk in atrial fibrillation
Q38972335	Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study.
Q36283049	Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study
Q41685690	Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin
Q36458873	Stroke in Atrial Fibrillation - Long-term Follow-up of Cardiovascular Events
Q34333317	Stroke in atrial fibrillation--hope on the horizon?
Q64255102	Stroke in atrial fibrillation: Review of risk stratification and preventive therapy
Q37635110	Stroke pharmacogenomics
Q37241354	Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar
Q37780750	Stroke prevention in atrial fibrillation patients
Q37827756	Stroke prevention in atrial fibrillation: atrial appendage closure
Q36382375	Stroke prevention in atrial fibrillation: concepts and controversies
Q30827866	Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice
Q38041072	Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants
Q24628390	Stroke prevention in atrial fibrillation: latest clinical trials and guidelines
Q38013062	Stroke prevention in atrial fibrillation: managing the risks in light of new oral anticoagulants
Q37801914	Stroke prevention in atrial fibrillation: putting the guidelines into practice
Q36241389	Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban
Q37945342	Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation.
Q37917579	Stroke prevention in nonvalvular atrial fibrillation
Q38113097	Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants
Q26781181	Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants
Q37800826	Stroke prevention in the high-risk atrial fibrillation patient: Medical management
Q52652655	Stroke prevention strategies in North American patients with atrial fibrillation: the GLORIA-AF registry program.
Q101038971	Stroke prevention strategies in high-risk patients with atrial fibrillation
Q37810505	Stroke prevention treatment of patients with atrial fibrillation: old and new.
Q36409072	Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach.
Q38411887	Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation.
Q37998367	Stroke prevention: an update
Q36418118	Stroke prevention: managing modifiable risk factors
Q51180285	Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Q64119729	Stroke risk stratification in atrial fibrillation: a review of common risk factors
Q38069194	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives
Q47162581	Stroke risks and patterns of warfarin therapy among atrial fibrillation patients post radiofrequency ablation: A real-world experience
Q51752354	Stroke severity in concomitant cardiac sources of embolism in patients with atrial fibrillation
Q38120570	Stroke thrombolysis in patients taking dabigatran
Q48341641	Stroke: more protection for patients with atrial fibrillation
Q82976978	Stroke: more trials, more answers
Q42944056	Strong force of industry
Q38133414	Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician.
Q90653595	Submassive Pulmonary Embolism and Left Atrial Thrombus
Q38728028	Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Q37226300	Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study
Q90467346	Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery
Q35962795	Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score
Q50055788	Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.
Q48240464	Successful intravenous thrombolysis following full dose rivaroxaban 5 hours before ictus
Q41413870	Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report
Q37299270	Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report
Q88610871	Successful treatment with idarucizumab for diffuse alveolar hemorrhage induced by dabigatran etexilate: a case report
Q37623214	Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology
Q37020922	Supervised patient self-testing of warfarin therapy using an online system
Q36235962	Supporting Treatment decision making to Optimise the Prevention of STROKE in Atrial Fibrillation: the STOP STROKE in AF study. Protocol for a cluster randomised controlled trial.
Q35579679	Supratherapeutic anticoagulation at presentation is associated with reduced mortality in nonvariceal upper gastrointestinal hemorrhage
Q37582479	Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
Q34954299	Surveying the medical literature: five notable articles in general internal medicine from 2008 and 2009.
Q93053567	Sustained resolution of anticoagulation related iron deficiency anemia with the use of apixaban
Q38254249	Switching between oral anticoagulants
Q35904418	Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
Q92655241	Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants
Q94600741	Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry
Q41138334	Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-1H-benzoimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors
Q38217011	Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation
Q36770313	Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2.
Q35798597	Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants
Q36021690	Systemic Embolic Events (SEE) in Atrial Fibrillation: SEEing Embolic Risk More Clearly
Q37295622	Systems-based approaches to cardiovascular disease
Q89128330	THE GAP BETWEEN ECONOMIC EVALUATIONS AND CLINICAL PRACTICE: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS ON DABIGATRAN FOR ATRIAL FIBRILLATION
Q26796466	TIA Management: Should TIA Patients be Admitted? Should TIA Patients Get Combination Antiplatelet Therapy?
Q38780134	Tailored treatment strategies: a new approach for modern management of atrial fibrillation.
Q38307541	Target-specific oral anticoagulants and the hospitalist
Q38053895	Target-specific oral anticoagulants for stroke prevention in patients with atrial fibrillation: real-world considerations
Q34650638	Target-specific oral anticoagulants in atrial fibrillation: results of phase III trials and comments on sub-analyses
Q38224011	Target-specific oral anticoagulants in patients undergoing cardioversion
Q38254246	Target-specific oral anticoagulants: practice issues for the clinician.
Q36680017	Targeted Anticoagulation for Atrial Fibrillation Guided by Continuous Rhythm Assessment With an Insertable Cardiac Monitor: The Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACT.COM) Pilot Study
Q37731832	Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy
Q37280316	Targeting platelet thrombin receptor signaling to prevent thrombosis
Q39026910	Targeting stroke risk and improving outcomes in patients with atrial fibrillation in Latin America
Q38076348	Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome
Q38781617	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges
Q47136340	Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.
Q48938691	Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype.
Q89581567	Ten-year trends in the incidence, treatment and outcomes of patients with mitral stenosis in Korea
Q44942447	Testing superiority at interim analyses in a non-inferiority trial
Q38646206	The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective
Q36847664	The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation
Q87858286	The Atrial Fibrillation Health Literacy Information Technology System: Pilot Assessment
Q57289953	The CHA₂DS₂-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
Q57157880	The Clinical Dilemma of Anticoagulation Use in Patients with Cerebral Amyloid Angiopathy and Atrial Fibrillation
Q28072579	The Cost Effectiveness of LAA Exclusion
Q37115008	The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation
Q43179594	The Dabigatran debate
Q53682358	The Effects of Dabigatran and Rivaroxaban on Markers of Polymorphonuclear Leukocyte Activation.
Q40033422	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary
Q38753709	The Evolution and Application of Cardiac Monitoring for Occult Atrial Fibrillation in Cryptogenic Stroke and TIA.
Q92359031	The Impact of Cancer on Major Bleeding and Stroke/Systemic Emboli in Patients Using Direct Oral Anticoagulants:From the Database of a Single-Center Registry
Q36396649	The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants
Q53695415	The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
Q28547424	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation
Q35028638	The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society.
Q90429817	The Management of Combined Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Particularly Complex Challenge, Especially in the Elderly
Q41190081	The Need for a Coagulation Assay after Initiation of New Oral Anticoagulants in Patients with Renal Dysfunction: A Case Report
Q42409130	The New Novel Oral Anticoagulants (NOACs) In Patients With Atrial Fibrillation: Dogma, Dilemmas, And Decisions On Dosing
Q47118947	The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations
Q38631121	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey
Q38774826	The Periprocedural Management of Anticoagulation and Platelet Aggregation Inhibitors in Endoscopic Interventions
Q36458835	The Potential Role of Edoxaban in Stroke Prevention Guidelines
Q61452037	The Prevalence and Risks of Inappropriate Combination of Aspirin and Warfarin in Clinical Practice: Results From WARFARIN-TR Study
Q37496155	The Prevalence of Low Left Atrial Appendage Emptying Velocity and Thrombus in Patients Undergoing Catheter Ablation for Atrial Fibrillation on Uninterrupted Peri-procedural Warfarin Therapy
Q43273421	The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin
Q30491580	The Reversal of Direct Oral Anticoagulants in Animal Models
Q91994890	The Risk of Stroke and Stroke Type in Patients With Atrial Fibrillation and Chronic Kidney Disease
Q37384677	The Role Of NOACs in Atrial Fibrillation Management: A Qualitative Study
Q64229164	The Role of Adherence Thresholds for Development and Performance Aspects of a Prediction Model for Direct Oral Anticoagulation Adherence
Q58776758	The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis
Q53292177	The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage.
Q38792322	The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation
Q92195579	The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes
Q37115131	The Safetyof Dabigatran Versus Warfarin in Patients Undergoing Atrial Fibrillation Ablation
Q42364461	The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials
Q39641019	The Severity of Bleeding and Mortality in Trauma Patients Taking Dabigatran
Q54961174	The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.
Q41067065	The Trends in Utilizing Nonvitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A Real-Life Experience.
Q47116446	The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series
Q38307591	The WATCHMAN device for stroke prophylaxis in atrial fibrillation: an evolving niche
Q42241079	The WATCHMAN left atrial appendage closure device for atrial fibrillation
Q37552621	The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
Q45879084	The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders
Q42595351	The adjustment of the type I error rate in noninferiority trials with λ-margin approach: each of two different new drugs is approved with two independent trials with the same active control
Q37851060	The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: an update
Q37812378	The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?
Q37030683	The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies
Q33441763	The atrial fibrillation epidemic is approaching the physician's door: will mobile technology improve detection?
Q37666333	The business case for quality improvement: oral anticoagulation for atrial fibrillation
Q35641960	The case for an elderly targeted stroke management
Q26776239	The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio
Q56987108	The challenge of preventing stroke in elderly patients with atrial fibrillation
Q38664920	The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use.
Q36635772	The changing characteristics of atrial fibrillation patients treated with warfarin
Q38120951	The changing face of oral anticoagulants
Q37014482	The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients
Q37823406	The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and post-bleed anticoagulant management
Q33848923	The clinical impact of different coagulometers on patient outcomes
Q35841143	The clinical relevance of cerebral microbleeds in patients with cerebral ischemia and atrial fibrillation
Q38880813	The contemporary management of intracranial atherosclerotic disease
Q38610543	The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.
Q38162274	The current status of bridging anticoagulation.
Q92565880	The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study
Q39266324	The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue
Q34403796	The debate on warfarin use in dialysis patients with atrial fibrillation: more fuel for the fire
Q47982176	The dilemma of atrial fibrillation in intracerebral haemorrhage: how to balance the risks of ischaemia and bleeding
Q37821752	The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Q41842059	The discovery of dabigatran etexilate
Q38829586	The discovery of dabigatran etexilate for the treatment of venous thrombosis
Q33928951	The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis
Q38026997	The economics of atrial fibrillation: a time for review and prioritization.
Q45716615	The effect of cognitive impairment in the elderly on the initial and long-term stability of warfarin therapy
Q53421834	The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers.
Q89802504	The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis
Q38176648	The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis
Q38108714	The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis.
Q38015427	The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review
Q38915687	The epidemic of pre-injury oral antiplatelet and anticoagulant use.
Q26771859	The evolution of anticoagulant therapy
Q27011873	The exact science of stroke thrombolysis and the quiet art of patient selection
Q39000179	The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation
Q38750444	The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
Q53110722	The hemorrhagic risk: how to evaluate it.
Q38097972	The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation
Q35205261	The impact of CHADS2 score on late stroke after the Cox maze procedure
Q35620065	The impact of age on the epidemiology of atrial fibrillation hospitalizations
Q38038960	The impact of antiplatelet and anticoagulant therapies on gastrointestinal symptoms in patients with atrial fibrillation: a systematic review
Q55100564	The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old.
Q38840977	The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review.
Q93083653	The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery
Q60920824	The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
Q51070334	The impact of surgical left atrial appendage amputation/ligation on stroke prevention in patients undergoing off-pump coronary artery bypass grafting.
Q47155761	The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis.
Q60305870	The incidence of left atrial appendage thrombi on transesophageal echocardiography after pretreatment with apixaban for cardioversion in the real-world practice
Q88432031	The influence of fibrate initiation on INR and warfarin dose in patients receiving chronic warfarin therapy
Q48700556	The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
Q37879680	The link between atrial fibrillation and stroke in women
Q37968514	The management of patients with atrial fibrillation and dronedarone's place in therapy
Q30647865	The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study
Q37959884	The management of stroke in antiphospholipid syndrome
Q37808230	The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention
Q43609145	The need for multicentre cardiovascular clinical trials in Asia
Q38717367	The new era of anticoagulation
Q27497485	The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature
Q82243554	The new oral anticoagulants
Q38263529	The new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy
Q37299820	The new oral anticoagulants in atrial fibrillation: an update
Q38122947	The new oral anticoagulants in atrial fibrillation: once daily or twice daily?
Q38053904	The new oral anticoagulants: a challenge for hospital formularies
Q38608530	The new oral anticoagulants: new uncertainties for endoscopists
Q38608541	The new oral anticoagulants: practical management for patients attending for endoscopic procedures
Q38203175	The newer direct oral anticoagulants: a practical guide.
Q39233249	The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review
Q53620115	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
Q34772923	The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation
Q51730521	The peri-procedural use of dabigatran in patients undergoing left atrial ablation for atrial fibrillation.
Q38080765	The pharmacology and therapeutic use of dabigatran etexilate
Q38122099	The pharmacology of novel oral anticoagulants
Q37873969	The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy.
Q43533823	The prestroke use of vitamin K antagonists for atrial fibrillation - trends over 15 years.
Q38735704	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients
Q37765619	The quest for new anticoagulants: from clinical development to clinical practice
Q48254861	The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation
Q48332345	The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation.
Q39022742	The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature
Q58420963	The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue
Q39530702	The role of anticoagulation clinics in the era of new oral anticoagulants
Q37939851	The role of apixaban for venous and arterial thromboembolic disease
Q36409803	The role of contraindications in prescribing anticoagulants to patients with atrial fibrillation: a cross-sectional analysis of primary care data in the UK.
Q38218874	The role of novel anticoagulants in the management of venous thromboembolic disease
Q33582537	The role of prothrombin complex concentrates in reversal of target specific anticoagulants
Q38198557	The role of rivaroxaban in atrial fibrillation and acute coronary syndromes
Q41399393	The role of soluble fibrin during anticoagulant therapy: a case report
Q38117730	The role of the laboratory in treatment with new oral anticoagulants
Q42180636	The safety and efficacy of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention: A meta-analysis
Q37468281	The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding: Long-term results from a multicenter study.
Q100696534	The safety of deep brain stimulation lead placement on patients requiring anti-clotting therapies
Q38598266	The safety of edoxaban for treating atrial fibrillation
Q64096935	The treatment pattern and adherence to direct oral anticoagulants in patients with atrial fibrillation aged over 65
Q58763661	The use of anticoagulants in patients with non-valvular atrial fibrillation between 2005 and 2014: A drug utilization study using claims data in Japan
Q46007747	The use of dabigatran immediately after atrial fibrillation ablation.
Q35028466	The use of vitamin K supplementation to achieve INR stability: a systematic review and meta-analysis
Q50193711	The year in cardiology 2017: arrhythmias and cardiac devices.
Q64931128	Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF.
Q38103768	Therapeutic drug monitoring for tomorrow.
Q44676772	Therapeutic management of non-valvular atrial fibrillation. Update 2013
Q90053693	Therapeutic strategies for thrombosis: new targets and approaches
Q35729599	Therapeutic strategies in acute intracerebral hemorrhage
Q36060497	Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants
Q87406978	Three-dimensional assessment of left atrial appendage orifice geometry and potential implications for device closure
Q42907046	Thrombi of Different Pathologies: Implications for Diagnosis and Treatment
Q38163395	Thrombin generation and atherosclerosis
Q38271983	Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice
Q91410741	Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice
Q38079287	Thrombin inhibitors: surgical considerations and pharmacology
Q33640335	Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke
Q34276182	Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis
Q37707396	Thrombocardiology: an update
Q94357376	Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry
Q33775289	Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study
Q36219093	Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry
Q37998109	Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor
Q38989053	Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study
Q47924174	Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion
Q40090031	Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases
Q48360578	Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report
Q46489865	Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke
Q87021874	Thrombosis on a mechanical mitral valve anticoagulated with dabigatran
Q37998001	Thrombosis: simplified
Q30625534	Thrombus formation in left atrium on dabigatran therapy
Q39254018	Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients.
Q47183789	Time to Revisit the Time in the Therapeutic Range
Q38526044	Time to reconsider dabigatran 110 mg in the USA.
Q64903567	Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation.
Q47281751	Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial
Q45895798	Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication
Q41036908	To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.
Q38532303	Tolerability and Acceptability of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Meta-Analysis
Q64994039	Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants.
Q38135335	Top 10 clinical research developments in antiphospholipid syndrome
Q38086147	Top practice-changing articles over the last two years
Q36877792	Total Thrombus-Formation Analysis System (T-TAS) Can Predict Periprocedural Bleeding Events in Patients Undergoing Catheter Ablation for Atrial Fibrillation
Q88196093	Transcatheter Aortic Valve Replacement and Left Atrial Appendage Occlusion - A Stitch in Time?
Q47897704	Transcatheter closure of the left atrial appendage: A focused update on the Watchman closure device.
Q37843744	Transforming oral anticoagulation by combining international normalized ratio (INR) self testing and online automated management
Q38187043	Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians
Q36957947	Transitions of care in anticoagulated patients
Q41971718	Transitions of care in anticoagulation management for patients with atrial fibrillation
Q22241760	Translatability scoring in drug development: eight case studies
Q93092190	Translation, Cultural Adaptation, and Psychometric Properties of the Danish Version of the Anti-Clot Treatment Scale
Q33581189	Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.
Q33165278	Traumatic fatal cerebral hemorrhage in an old patient with a history of multiple sclerosis under dabigatran: a case report and review of the literature
Q38701940	Treating Specialty and Outcomes in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study
Q37847185	Treating arrhythmias: an expert opinion
Q42290326	Treating patients on new anticoagulant drugs
Q38942382	Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
Q36057729	Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States
Q64998425	Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population.
Q38111097	Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment
Q35648056	Treatment of acute ischemic stroke: beyond thrombolysis and supportive care
Q90245863	Treatment of atrial fibrillation in nursing homes: A place for direct acting oral anticoagulants?
Q38060565	Treatment of dabigatran-associated bleeding: case report and review of the literature
Q49990585	Treatment of gastrointestinal bleeding with idarucizumab in a patient receiving dabigatran.
Q35648075	Treatment of risk factors to prevent stroke
Q37773994	Treatment of thromboembolism in cancer patients
Q36561057	Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management
Q37733553	Treatment options for deep vein thrombosis.
Q48356499	Trend of Prevalence of Atrial Fibrillation and use of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation in South Korea (2002-2013).
Q89153310	Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017
Q38551723	Trends in Warfarin Monitoring Practices Among New York Medicare Beneficiaries, 2006-2011.
Q36203436	Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands
Q52618065	Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.
Q37135634	Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study
Q38403042	Trends in oral anticoagulant use in Qatar: a 5-year experience.
Q33552982	Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants
Q33424198	Trends in the development of oral anticoagulants
Q36449900	Trends in the management of atrial fibrillation: A neurologist's perspective
Q38733238	Trends in the prescription of novel oral anticoagulants in UK primary care
Q48361310	Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
Q88395076	Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation
Q90274805	Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012-2017
Q85093103	Trial watch: apixaban beats warfarin in stroke trial
Q51805253	Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review.
Q89397561	Triple Therapy: When, if Ever?
Q37463805	Triple anticoagulation therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention - real life assessment
Q36411732	Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis
Q38035268	Triple antithrombotic therapy in patients with atrial fibrillation who have undergone percutaneous coronary intervention with stent implantation.
Q38543313	Triple therapy for percutaneous coronary intervention in atrial fibrillation: standard of care, or a nightmare soon to end?
Q38092567	Tutorial in oral antithrombotic therapy: biology and dental implications
Q28539517	Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria
Q92313821	Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
Q26852765	Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice
Q42377391	Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed
Q37626681	Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR)
Q37115706	Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease
Q37164143	Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future
Q38668964	Underuse of anticoagulation in patients with atrial fibrillation
Q50067395	Underuse of vitamin K antagonist and direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: A contemporary review.
Q45327851	Unfractionated heparin anticoagulation using estimated blood volume based dosing versus weight-based dosing in a Veteran population.
Q44712997	Unique evolution of Bivalvia arginine kinases
Q50950032	Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.
Q39135634	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban
Q41929780	Unrestricted prescription of dabigatran: Is it safe in a resource-limited setting
Q28081837	Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options
Q26992000	Untreated atrial fibrillation in the United States of America: Understanding the barriers and treatment options
Q83151121	Update in cardiology
Q37052828	Update in intracerebral hemorrhage
Q30249060	Update in perioperative medicine: practice-changing evidence published in 2015.
Q34332967	Update of the Preventive Antibiotics in Stroke Study (PASS): statistical analysis plan
Q38849824	Update on Anticoagulation: What the Interventional Radiologist Needs to Know
Q35172841	Update on anti-coagulation in atrial fibrillation
Q33814131	Update on antithrombotic therapy for stroke prevention in atrial fibrillation
Q37642825	Update on perioperative bridging in patients on chronic oral anticoagulation.
Q37959147	Update on the clinical management of atrial fibrillation: guidelines and beyond
Q37899797	Update on the management of atrial fibrillation: anticoagulation and medical therapy
Q55359342	Updates on Prevention of Cardioembolic Strokes.
Q39159043	Upper gastrointestinal endoscopy in emergency setting for patients receiving oral anticoagulants - practice updates
Q38083884	Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs.
Q90249239	Uppsala Clinical Research Center-development of a platform to promote national and international clinical science
Q38941069	Upstream versus downstream thrombin inhibition
Q42950094	Usage of Dabigatran versus Warfarin for Patients with Atrial Fibrillation
Q55220400	Use Patterns and Unlabeled Uses of Target-Specific Oral Anticoagulants: A Single-Center Experience.
Q39745976	Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran
Q37022918	Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation.
Q64988900	Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.
Q26764853	Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions
Q52805260	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.
Q31066944	Use of Direct-Acting Oral Anticoagulants in Nonagenarians: A Call for More Data
Q45975657	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Q47153532	Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective
Q90610508	Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience
Q38496232	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice
Q46042485	Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1.
Q57818803	Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation
Q39232066	Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.
Q53092878	Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose.
Q38911632	Use of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centre
Q36944900	Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.
Q33553657	Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence
Q61449791	Use of direct oral anticoagulants in daily practice
Q38655829	Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.
Q38812464	Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile
Q30978916	Use of genetic data to guide therapy in arterial disease
Q89667718	Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function
Q58720024	Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
Q37844143	Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment
Q38104683	Use of new oral anticoagulants in antiphospholipid syndrome
Q34099930	Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective
Q38998384	Use of novel oral anticoagulant agents in venous thromboembolism
Q87056045	Use of novel oral anticoagulants in patients with heart failure
Q35654365	Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?
Q90018927	Use of oral anticoagulants in complex clinical situations with atrial fibrillation
Q92023065	Use of oral anticoagulants in older people with atrial fibrillation in UK general practice: protocol for a cohort study using the Clinical Practice Research Datalink (CPRD) database
Q88172233	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction
Q37073792	Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
Q86568648	Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation
Q92218894	Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal
Q38411840	Using new oral anticoagulants in patients undergoing major orthopedic surgery
Q52677753	Using the Symmetry Analysis Design to Screen for Adverse Effects of Non-vitamin K Antagonist Oral Anticoagulants.
Q38312159	Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience
Q30842114	Utilization and prescribing patterns of direct oral anticoagulants
Q36161194	Utilization of Dabigatran for Atrial Fibrillation at 3 Tertiary Care Centres
Q34110818	Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation.
Q34474337	Validation of a simple method for atrial fibrillation screening in patients with stroke.
Q58574398	Validity of electronic hospital discharge prescription records as a source of medication data for pharmacoepidemiological research
Q36304292	Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation.
Q43831345	Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives
Q86211132	Variability in the benefit of the novel oral anticoagulant agents in patients with non-valvular atrial fibrillation
Q36257208	Variability of the Left Atrial Appendage in Human Hearts
Q88598737	Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function : Post hoc analysis of a prospective cohort
Q37763262	Vascular PAR-1: activity and antagonism
Q26766262	Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care
Q30244606	Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics.
Q43198338	Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit
Q26746062	Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences
Q91759926	Vitamin K antagonist vs direct oral anticoagulants with antiplatelet therapy in dual or triple therapy after percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation: Meta-analysis of randomized controlled trials
Q38086125	Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement
Q47685113	Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
Q54487679	Vitamin K antagonists, direct oral anticoagulants, and the rationale for reversal agents.
Q39023182	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
Q82788303	Vitamin K antagonists: self-determination by self-monitoring?
Q61818267	Vitamin K in Chronic Kidney Disease
Q95513754	Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
Q60919978	Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution
Q57626878	Vorhofflimmern
Q36689643	Warfarin Dosing Algorithms and the Need for Human Intervention
Q28468726	Warfarin Pharmacogenetics: New Life for an Old Drug
Q40704670	Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study
Q44463959	Warfarin Use and Increased Mortality in End-Stage Renal Disease
Q47106586	Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes
Q43161129	Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial
Q37045277	Warfarin and aspirin in patients with heart failure and sinus rhythm
Q37607493	Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
Q89287150	Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE
Q42088198	Warfarin improved CT values of the coronary artery artherosclerotic plaque: evaluation by 64-MDCTA.
Q35985876	Warfarin in atrial fibrillation patients with moderate chronic kidney disease
Q53090842	Warfarin or dabigatran for treatment of atrial fibrillation.
Q30766944	Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data
Q45116644	Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)).
Q38262325	Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
Q40787630	Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin
Q39037014	Watchman Device: Left Atrial Appendage Closure For Stroke Prophylaxis In Atrial Fibrillation
Q39659277	Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off?
Q43114285	Well-managed warfarin is superior to NOACs
Q34288423	What are the emerging therapeutic alternatives to warfarin in stroke patients? How would the results of RE-LY benefit Pakistanis?
Q38048533	What did we learn from new oral anticoagulant treatment?
Q38195315	What is the role of renal replacement therapy in the setting of dabigatran toxicity?
Q37820332	What is the role of the cardiologist in future management of stroke prevention in atrial fibrillation?
Q43067611	When a virtue becomes a problem. The new oral anticoagulants
Q30979218	Where will the next generation of stroke treatments come from?
Q37456963	Which Factors Influence Resident Physicians to Prescribe NOACs to Patients with Non-Valvular Atrial Fibrillation?
Q37004184	Who Were the Early Adopters of Dabigatran?: An Application of Group-based Trajectory Models
Q36241151	Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland
Q38655960	Who, when, and how to reverse non-vitamin K oral anticoagulants
Q38615648	Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?
Q38773090	Why switch from warfarin to NOACs?
Q37756353	Will warfarin ever be replaced?
Q35194074	Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence
Q36773866	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
Q35960738	Young Male Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study
Q84912890	[Acute ischemic stroke. New approaches to antithrombotic treatment]
Q82734942	[Advances made in the past year (2009) in the therapeutic approach to hypertensive heart disease, myocardial ischemia, and atrial fibrillation]
Q82104773	[Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure]
Q84025400	[Anticoagulants and dual antiplatelet therapy combined, a challenge to our intelligence]
Q52840065	[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].
Q84149254	[Anticoagulation. Modern concepts]
Q84301516	[Anticoagulation. Start of a new era?]
Q86011424	[Atrial appendage occlusion in atrial fibrillation? Con]
Q83551945	[Atrial fibrillation : new anticoagulants and antiarrhythmic drugs]
Q83179016	[Cardiac electrophysiology and arrhythmias]
Q87585293	[Cardiovascular pharmacotherapy. Risks and adverse effects]
Q52848552	[Catheter-based closure of the left atrial appendage : Stroke prevention in atrial fibrillation].
Q84340751	[Clinical management of the new anticoagulants]
Q56769427	[Clinical research XXIV. From clinical judgment to ethics in research on humans]
Q52848195	[Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation].
Q85669740	[Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants]
Q92858640	[Contribution of Holter ECG in the etiologic diagnosis of the ischemic stroke in Brazzaville, Congo]
Q87423272	[Current registry studies of acute ischemic stroke]
Q86704231	[Current treatment of tachycardia]
Q85334975	[Dabigatran: beyond the RE-LY study]
Q85334982	[Dabigatran: transforming the management of oral anticoagulation]
Q52893837	[Difficult decisions in stroke therapy].
Q87795069	[Direct anticoagulants for atrial fibrillation. Update 2014]
Q53511051	[Direct oral anticoagulation and gastrointestinal bleeding: Interventional therapy management].
Q50229419	[Fine-tuning of antithrombotic therapy in patients with non-valvular atrial fibrillation. The AFINVA register].
Q92279352	[GRADE: Evidence to Decision (EtD) frameworks - a systematic and transparent approach to making well informed healthcare choices. 2: Clinical guidelines]
Q86563603	[Interventional stroke prophylaxis : endocardial and epicardial left atrial appendage closure]
Q85563910	[Intracranial hemorrhage: diagnosis, prognosis, acute treatment and secondary prophylaxis]
Q85334804	[Introduction]
Q54184682	[Management and therapy of atrial fibrillation in geriatric patients].
Q50959098	[Management of NOAK administration during invasive or surgical interventions : When and how to pause and when to restart?]
Q52665628	[Management of hemorrhage in patients treated with direct oral anticoagulants].
Q85334810	[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? No]
Q85334807	[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes]
Q84007372	[New anticoagulants for stroke prevention in atrial fibrillation]
Q87764754	[New direct oral anticoagulants : Many advantages, but open questions]
Q85524163	[New oral anticoagulants and chronic kidney disease]
Q52887413	[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
Q83346650	[New oral anticoagulants in atrial fibrillation]
Q87050930	[New oral anticoagulants: who really needs them?]
Q82736947	[New perspectives on oral preventive anticoagulants]
Q84025398	[Non valvular atrial fibrillation: the neurologist's perspective]
Q53535820	[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].
Q54127394	[Oral anticoagulant-associated intracerebral haemorrhage].
Q87345927	[Oral anticoagulation for atrial fibrillation]
Q84301950	[Oral factor Xa inhibitors or warfarin for stroke prophylaxis. ROCKET AF and ARISTOTLE studies]
Q94207195	[Perception of physicians on factors that influence the choice of a dicoumarin or a new oral anticoagulant in patients with non-valvular atrial fibrillation]
Q88460453	[Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks]
Q54653980	[Perioperative management of patients on NOACs].
Q84080026	[Pharmacology of the new oral anticoagulants]
Q86645996	[Pre-interventional, peri-interventional and post-interventional anticoagulation in the setting of catheter ablation for atrial fibrillation : current practice and practical approach]
Q84025393	[Prevention of thromboembolism in atrial fibrillation]
Q90402294	[Primary Prevention of Acute Stroke]
Q52886232	[Primary and secondary prevention of stroke].
Q89500667	[Procedures on patients receiving NOACs : What's possible?]
Q83320633	[Progress in clinical cardiology. The clinical cardiologist's response to new cardiovascular drugs]
Q86693570	[Rate and rhythm control in atrial fibrillation : pharmacological approaches]
Q50171944	[Recent and upcoming randomized trials for left atrial appendage occlusion : Need for a definite assessment of the situation].
Q84550979	[Report of the 2nd NeuroUpdate from the MedUpdate series in Wiesbaden]
Q87913565	[Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology]
Q84080027	[Role of the new oral anticoagulants in comparison to vitamin K antagonists in practice]
Q49670153	[S1 guideline - Austrian consensus for anticoagulation in the context of atrial fibrillation ablation].
Q85334978	[Scope of the latest RE-LY substudies: clinical implications]
Q86694448	[Stroke prevention in atrial fibrillation : old and new anticoagulants]
Q87907905	[Stroke prophylaxis in atrial fibrillation : When, how and for whom?]
Q89156238	[The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease]
Q84919701	[Treatment of chronic left ventricular failure]
Q86910060	[Treatment safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation]
Q90325793	[Update on antithrombotic secondary prevention of ischemic stroke]
Q83179007	[Update on geriatric cardiology]
Q83320616	[Update on geriatric cardiology]
Q53536784	[Vitamin K antagonists : Is their prescription really "medical malpractice" today?]
Q38812513	e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study.
Q61799899	β-arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial function via PDGF-β in stroke
Q38996320	γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.

P356	DOI	10.1056/NEJMOA0905561
P3181	OpenCitations bibliographic resource ID	539011
P698	PubMed publication ID	19717844

P50	author	Salim Yusuf	Q2214381
		Lars Wallentin	Q6230815
		Hans-Christoph Diener	Q25935337
		John W. Eikelboom	Q42846212
		Muredach P. Reilly	Q51505621
		Janice Pogue	Q82061920
		Jonas Oldgren	Q106086753
		Michael D. Ezekowitz	Q110902282
		A Marco Alings	Q114402800
		Harald Darius	Q114427096
		Campbell D Joyner	Q114453050
		Amit Parekh	Q114775425
		Ellison Themeles	Q114775426
		Jeanne Varrone	Q114775427
P2093	author name string	Jun Zhu
		Rafael Diaz
		Basil S Lewis
		Denis Xavier
		Stuart J Connolly
		Susan Wang
P433	issue	12
P407	language of work or name	English	Q1860
P921	main subject	(RS)-warfarin	Q407431
		dabigatran	Q419345
		atrial fibrillation	Q815819
P304	page(s)	1139-51
P577	publication date	2009-09-17
P1433	published in	The New England Journal of Medicine	Q582728
P1476	title	Dabigatran versus warfarin in patients with atrial fibrillation
P478	volume	361

Dabigatran versus warfarin in patients with atrial fibrillation

scientific article

Reverse relations